DMID Protocol 15-0037  Version 11.0 
 
Renal Pharmacokinetics  11 April  2024  
 
A Phase 1, Open- Label, Single- Dose Study to Evaluate the 
Pharmacokinetics and Safety of  Pretomanid in Participants with 
Renal  Impairment  Compared  to Participants  with  Normal  Renal 
Function  
 
Division  of Microbiology and Infectious  Diseases  (DMID)  Protocol  Number:  
15-0037 
 
 
DMID  Funding Mechanism: Vaccine  and Treatment  Evaluation  Units 
 
 
Pharmaceutical Support: TB Alliance  
  
Investigational  New  Drug  (IND)  Sponsor: DMID, National  Institute  of Allergy 
and Infectious Diseases (NIAID) 
 
 
Principal  Investigators: William  Smith,  MD and Kimberly  Cruz,  MD 
 
 
 
 
DMID  Clinical Project  Manager: Erica Sondergaard,  RN, BSN, CCRC  
 
 
Version:  11.0 
11 April 2024 
 
 
 
i 
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
2  
  
STATEMENT OF ASSURANCE  
 
Each  Institution  will hold a current  Federal  Wide  Assurance  (FWA)  issued  by [CONTACT_168713] (OHRP) for federally funded human participants research. Each FWA will 
designate at least one Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
registered with OHRP, for which the research will be reviewed and approved by [CONTACT_1201]/IEC and will be participant to continuing review  [45 CFR 46.103(b)]. The IRB/IEC designated under  an FWA 
may include an institution’s  IRB/IEC,  an independent IRB/IEC,  or an IRB/IEC  of another institution 
after establishing a written agreement with that other institution.  
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
3  
  
STATEMENT OF COMPLIANCE  
 
The study trial will be carried  out in accordance with Good Clinical Practice  (GCP)  and as 
required by [CONTACT_716]: 
• [LOCATION_002] Code of Federal Regulations (CFR) 45 CFR Part 46 (Protection of Human 
Subjects)  
• Food and Drug  Administration  (FDA)  Regulations, as applicable: 21 CFR Part 50 (Protection  of 
Human  Subjects),  21 CFR  Part 54 (Financial  Disclosure by [CONTACT_168714]),  21 CFR Part 
56 (Institutional Review Boards), 21 CFR Part 312 (Investigational New Drug Application 
[IND] Application), 21 CFR 812 (Investigational Device Exemptions)  
• International Council for Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) E6(R2) GCP: Integrated Addendum to ICH E6(R1) Guidance for Industry, published in the Federal Register (83 FR 8882 [2018]), including the latest finalized revision
 
• Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research  
• National Institutes  of Health  (NIH)  Office  of Extramural Research,  Research Involving Human 
Subjects, as applicable  
• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Terms of Award, as 
applicable  
• Applicable federal, state,  and local regulations and guidance  
DMID  Protocol  15-[ADDRESS_196638] the study in accordance with the current protocol and will not make changes to 
the protocol without obtaining the sponsor’s approval and IRB/IEC approval, except  when  necessary 
to protect the safety, rights, or welfare of participants.  
 
 
Site Inve stigator  Signature:   
 
 
[INVESTIGATOR_14586]:    
 
Date:  
William  Smith, MD 
 
Alliance  for Multispecialty  Research  (AMR) 
[ADDRESS_196639] the study in accordance with the current protocol and will not make changes to 
the protocol without obtaining the sponsor’s approval and IRB/IEC approval, except  when  necessary 
to protect the safety, rights, or welfare of participants.  
 
 
Site Inve stigator  Signature:   
 
 
[INVESTIGATOR_14586]:    
 
Date:  
 Kimberly  Cruz,  MD 
 
Advanced Pharma  CR 
[ADDRESS_196640] OF ABBREVIATIONS  ........................................................................................................ 12 
PROTOCOL  SUMMARY  ............................................................................................................. 15 
1 KEY ROLES ......................................................................................................................... 20 
2 BACKGROUND INFORMATION AND SCIENTIFIC  RATIONALE  .............................. 21 
Background  ............................................................................................................... 21 
 Tuberculosis  .................................................................................................. 21 
 Tuberculosis in Patients  with Renal  Impairment .......................................... 22 
 Pretomanid  .................................................................................................... 22 
 Pre-Clinical Animal Studies  .......................................................................... 23 
 Clinical Trials  for Safety  and Pharmacokinetics  ........................................... 24 
 Efficacy  Studies  ............................................................................................ 26 
Scientific  Rationale  ................................................................................................... 30 
 Purpose of Study  ........................................................................................... 30 
 Study Population  ........................................................................................... 31 
Potential Risks and Benefits  ...................................................................................... 31 
 Potential Risks  ............................................................................................... 31 
 Potential Benefits  .......................................................................................... 33 
3 STUDY  DESIGN,  OBJECTIVES,  AND ENDPOINTS  OR OUTCOME  MEASURES ..... 34 
Study Design Description  .......................................................................................... 34 
Study Objectives  ....................................................................................................... 35 
 Primary  .......................................................................................................... 35 
 Secondary  ...................................................................................................... 35 
Study Endpoints or Outcome Measures .................................................................... 35 
 Primary  .......................................................................................................... 35 
 Secondary  ...................................................................................................... 36 
4 STUDY  INTERVENTION/INVESTIGATIONAL  PRODUCT  .......................................... [ADDRESS_196641] Storage and Stability  ........................................................................ 37 
Acquisition/Distribution  ............................................................................................ 38 

DMID  Protocol  15-0037  Version  11.0 
7  
 Renal Pharmacokinetics  11 April  2024  
Dosage/Regimen, Preparation, Dispensing, and Administration of Study 
Intervention/Investigational Product  ......................................................................... 38 
Pre-determined Modification of Study Intervention/Investigational Product for an  
Individual Participant ................................................................................................ 39 
Accountability Procedures for the Study Intervention/ Investigational Product(s)  ... 39 
5 SELECTION  OF PARTICIPANTS  AND  STUDY ENROLLMENT AND WITHDRAWAL  
. .............................................................................................................................................. 40 
Eligibility  Criteria  ..................................................................................................... 40 
 Participant  Inclusion Criteria  ........................................................................ 40 
 Participant  Exclusion Criteria  ....................................................................... 42 
Withdrawal  from the Study or Study Termination  .................................................... 46 
 Withdrawal  from the Study  ........................................................................... 46 
 Participant  Replacement  ................................................................................ 47 
 Study Termination  ......................................................................................... 47 
6 STUDY  PROCEDURES  ....................................................................................................... 48 
Screening  ................................................................................................................... 48 
 Visit 00A, Screening  Clinic  Visit  (Day  -28 to -7)......................................... 48 
 Visit 00B, 2nd Screening Clinic  Visit (Day -28 to -7) ................................... 48 
 Visit 00C, Hospi[INVESTIGATOR_91595], Day -1 ........................................................ 49 
Dosing (Day  1) and In-house Confinement/ PK C
ollection  ..................................... [ADDRESS_196642]  ................................................. 50 
 Visit 01B, Day 1, Time 1 Hour ± [ADDRESS_196643]-dose; Hospi[INVESTIGATOR_7985]  ...... 51 
 Visit 01C, Day 1, Time  2 Hours ± [ADDRESS_196644]-dose; Hospi[INVESTIGATOR_7985]  ..... 51 
 Visit 01D, Day 1, Time  4 Hours ± [ADDRESS_196645]-dose; Hospi[INVESTIGATOR_7985]  ..... 52 
 Visit 01E, Day 1, Time 5 Hour ± [ADDRESS_196646]-dose; Hospi[INVESTIGATOR_7985]  ....... 52 
 Visit 01F, Day 1, Time 6 Hours ± [ADDRESS_196647]-dose; Hospi[INVESTIGATOR_7985]  ..... 52 
 Visit 01G, Day 1, Time 8 Hour ± [ADDRESS_196648] -dose; Hospi[INVESTIGATOR_7985]  ...... 53 
 Visit 01H, Day 1, Time  12 Hours ± [ADDRESS_196649]-dose; Hospi[INVESTIGATOR_7985] ... 53 
 Visit 01I, Day 1, Time  16 Hour ± [ADDRESS_196650]-dose; Hospi[INVESTIGATOR_7985]  ...... 53 
 Visit 01J, Day 2, Time 24 Hour ± [ADDRESS_196651]- dose; Hospi[INVESTIGATOR_7985]  ............ 54 
 Visit 01K, Day 2, Time 36 Hour ± [ADDRESS_196652]- dose; Hospi[INVESTIGATOR_7985]  ..........  54 
 Visit 01L, Day 3, Time 48 Hours ± [ADDRESS_196653]-dose, Hospi[INVESTIGATOR_7985] .......... 54 
Follow -Up ................................................................................................................. 55 
 Visit 01M, Day 4, Time 72 Hours ± [ADDRESS_196654]-dose, Clinic Visit .......... 55 
 Visit 01N, Day 5, Time  96 Hours ± [ADDRESS_196655]-dose, Clinic Visit ........... 56 
 Visit 02, Day 12 ± [ADDRESS_196656]-dose, Clinic Visit  ........................................ 56 
Final  Visit, Visit 03, Day 85+[ADDRESS_196657]-dose, Phone  Visit  ................................... 57 
Early  Termination  Visit (if needed)  .......................................................................... 57 
Unscheduled Visit (if needed)  ................................................................................... 58 
Protocol Deviations  ................................................................................................... 58 
7 DESCRIPTION  OF CLINICAL  AND LABORATORY  EVALUATIONS  ........................ 59 

DMID  Protocol  15-0037  Version  11.0 
8  
 Renal Pharmacokinetics  11 April  2024  
Clinical Evaluations  .................................................................................................. 59 
 Assessment of Concomitant Medications/Treatments Other Than Study  
Product  .......................................................................................................... [ADDRESS_196658] Values or  
Abnormal Clinical  Findings  ...................................................................................... 69 
Halting  Rules  ............................................................................................................. 69 
 Study Halting Criteria  ................................................................................... 69 
Safety  Oversight  ........................................................................................................ 70 
 Safety  Monitoring Committee  (SMC)  .......................................................... [ADDRESS_196659]  ....................................................................................... 71 
Informed  Consent Process ......................................................................................... 71 
Special  Populations  ................................................................................................... 73 
Participant  Confidentiality  ........................................................................................ 73 
Certificate  of Confidentiality  ..................................................................................... 74 
Costs,  Participant Compensation, and Research  Related  Injuries  ............................. 74 
10 STATISTICAL CONSIDERATIONS  .................................................................................. 76 
 Study Hypotheses  ...................................................................................................... 76 
 Sample  Size Considerations  ......................................................................................  76 
 Treatment  Assignment  Procedures  ............................................................................ 77 
 Randomization Procedures ............................................................................ 77 
10.3.2 Masking  Procedures  ...................................................................................... 78 
 Planned Interim Analyses  .......................................................................................... 78 
 Interim Safety and PK Review  ...................................................................... 78 
 Final  Analysis Plan .................................................................................................... 78 
 Analysis Populations ..................................................................................... 78 
 Analysis of Primary Endpoint (PK for Pretomanid)  ..................................... 78 
 Analysis of Secondary Endpoint (Safety) ..................................................... 79 

DMID  Protocol  15-0037  Version  11.0 
9  
 Renal Pharmacokinetics  11 April  2024  
 Analysis of Secondary Endpoint (PK for M19 and M50) ............................ 81 
11 ELECTRONIC CASE REPORT FORMS AND ACCESS TO SOURCE  
DATA/DOCUMENTS  .......................................................................................................... [ADDRESS_196660] KEEPI[INVESTIGATOR_1645]  ................................................................. 84 
 Data  Management  Responsibilities  ........................................................................... 84 
 Data  Coordinating Center/Biostatistician  Responsibilities  ....................................... 84 
 Data  Capture Methods  ............................................................................................... 84 
 Types of Data ............................................................................................................ 84 
 Study Records Retention  ........................................................................................... 84 
14 CLINICAL  MONITORING ................................................................................................. 86 
15 PUBLICATION POLICY  ..................................................................................................... 87 
16 LITERATURE  REFERENCES ............................................................................................ 88 
17 APPENDICES  ....................................................................................................................... 91 
APPENDIX  A: Schedule of Study Procedures and Evaluations  ................................................... 92 
APPENDIX  B: Venipuncture Volumes (mL)  ................................................................................ [ADDRESS_196661] OF TABLES  
 
Table  1: Study Design  ............................................................................................................... 18 
Table  2: Summary  of Phase 2 studies using Pretomanid  .......................................................... 28 
Table  3: Pretomanid  Formulation .............................................................................................. 37 
Table 4: Prohibited Strong and Moderate CYP450 Enzyme Inducer or Inhibitor  
Medications/Substances per Participant Exclusion Criteria  ....................................... [ADDRESS_196662] OF FIGURES  
Figure 1: Schematic of Study Design  ......................................................................................... 19 
Figure 2: Chemical  Structure  of Pretomanid  .............................................................................. 22 
Figure 3: Probability  of Observing at Least  50% Increase by [CONTACT_168715] .......................................................................................................... [ADDRESS_196663] OF ABBREVIATIONS 
 
Advantage  eClinical® Electronic  Data  Capture  System  
AE Adverse  Event/Adverse  Experience  
ALT Alanine  Aminotransferase  
AST Aspartate  Aminotransferase  
AUC  Area  under  the plasma  concentration -time curve  
AUC ∞ Area  under  the plasma  concentration -time curve  from  time [ADDRESS_196664] 
measurement  
A-V Atrioventricular  
BCG  Bacillus  Calmette -Guérin  
BDQ  Bedaquiline  
BMI Body  Mass  Index  
BPaL  Pretomanid,  Bedaquiline,  and Linezolid  
BPM  Beats  Per Minute  
BUN  Blood  Urea  Nitrogen  
Cavg Average  Concentration  Over  a Dosing  Interval  
CFR Code  of Federal Regulations  
CFU Colony  Forming  Unit 
CG Cockcroft -Gault  
CHF Congestive  Heart  Failure  
CI Confidence  Interval  
CKD  Chronic  Kidney  Disease  
CL/F  Apparent  Clearance  
CL R Renal  Clearance  
Cmax Maximum  plasma  concentration  
CMS  Clinical  Materials  Services  
CROMS  Clinical  Research  Operations  & Management  Support  
CTCAE  Common  Terminology  Criteria  for Adverse  Events  
CV Coefficients  of Variation  
CYP450  Cytochrome  P450  
°C Degrees  Celsius  
°F Degrees  Fahrenheit  
DCC  Data  Coordinating  Center  
DCF Data  Collection  Form  
DHHS  Department  of Health  and Human  Services  
dL Deciliter  
DMID  Division  of Microbiology  and Infectious  Diseases,  NIAID,  NIH 
DOTS  Directly  Observed  Therapy  Short  Course  
EBA  Early  Bactericidal  Activity  
ECG  Electrocardiogram  
DMID  Protocol  15-[ADDRESS_196665]  End Stage  Renal  Disease  
ET Early  Termination  
FDA  Food  and Drug Administration  
FWA  Federal  Wide  Assurance  
g/dL Grams  per Deciliter  
GCP Good  Clinical  Practice  
GFR Glomerular  Filtration  Rate 
HBsAg  Hepatitis  B surface  antigen  
HBV  Hepatitis  B virus  
HCG  Human  Chorionic  Gonadotropin  
HCV  Hepatitis  C virus  
Hgb Hemoglobin  
HRZE  Standard  Treatment  with Isoniazid,  Rifampin,  Pyrazinamide,  and 
Ethambutol  
IATA  International  Air Transport  Association  
IB Investigator’s  Brochure  
ICF Informed  Consent Form  
ICH International  Council  for Harmonisation  
IEC Independent  Ethics  Committee  
IND Investigational  New  Drug  Application  
INH Isoniazid  
IRB Institutional  Review  Board  
kg Kilogram  
LLT Low Level  Term  
LZD Linezolid  
µg Microgram(s)  
µL Microliter(s)  
MDRD  Modification  of Diet in Renal  Disease  
MDR -TB Multidrug -Resistant  Tuberculosis  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
mg Milligram  
mg/dL  Milligram(s)  per Deciliter  
MIC Minimum  Inhibitory  Concentration  
mL Milliliter(s)  
mm Millimeter(s)  
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
14  
  
 
mmHg  Millimeters  of Mercury  
msec  Millisecond  
MOP  Manual  of Procedures  
Mtb Mycobacterium  tuberculosis  
N Number  of Participants  
NIAID  National  Institute  of Allergy  and Infectious  Diseases,  NIH,  DHHS  
NIH National  Institutes  of Health  
NO Nitric  Oxide  
OER  Office  of Extramural  Research  
OHRP  Office  for Human  Research  Protections  
PHI Personal  Health  Information  
PI [INVESTIGATOR_168678]/Serious  Adverse  Experience  
SDCC  Statistical  and Data  Coordinating  Center  
SMC  Safety  Monitoring  Committee  
SOC System  Organ  Class  
SZD Sutezolid  
t1/2 Elimination  Half-life 
TB Tuberculosis  
TEAE  Treatment  Emergent  Adverse  Event  
TI Treatment -intolerant  
Tmax Time  to maximum  (peak)  plasma  drug concentration  
ULN  Upper  Limit  of Normal  
US United  States  
Vd/F Volume  of distribution  
WHO  World  Health  Organization  
XDR -TB Extensively  Drug -Resistant  TB 
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
15  
  
PROTOCOL  SUMMARY 
 
 
Title:  A Phase 1, Open -Label, Single -Dose Study to Evaluate the 
Pharmacokinetics and Safety of Pretomanid in Participants with 
Renal Impairment Compared to Participants with Normal Renal 
Function  
Design  of the Study:  This is a Phase  1, open- label,  single -dose,  sequential  group study  to 
compare the safety  and pharmacokinetics  (PK)  of pretomanid  in the 
following groups of participants: 1) participants with severe renal 
impairment including those with end stage renal disease (ESRD) not 
on dialysis, and participants with mild or moderate renal 
impairment, designated as Groups 2, 3, and 4, respectively; and 2) 
participants with normal renal function matched to the above renal 
impairment groups, designated as Groups 1A, 1B, and 1C, 
respectively.  
The study will be conducted following a reduced PK study design 
in Part A, see Table  1 and Figure 1.  Part A will enroll participants 
from Group 1A (i.e., 6 healthy matched  controls) and Group 2 (i.e., 
[ADDRESS_196666], not on 
dialysis).  A decision to proceed  to Part B will be made after the PK 
of pretomanid, and safety in participants enrolled in Part A have 
been reviewed. If Part A demonstrates at least a 50% increase in 
pretomanid  area under the plasma concentration- time curve  (AUC) 
in Group 2 (severe renal impairments and ESRD, not on dialysis) 
relative to the exposures in Group 1A (matched participants with 
normal renal  function), then the reduced  PK study will extend to the 
full PK study to enroll participants into Part B (i.e., to investigate 
mild and moderate renal  impairment).  All Part B groups (1B, 1C, 3, 
and 4) will be enrolled concurrently. 
If the reduced PK study shows at least a 50% increase in AUC in 
patients with severe renal impairment and patients with ESRD not 
yet on dialysis  relative  to the matched  healthy controls,  a “full  PK” 
renal impairment study in patients with all intermediate levels of 
renal function impairment should be conducted. Otherwise, no 
further study is recommended.  
Study  Population:  Total [ADDRESS_196667]  each of the renal  impairment  groups,  and 18 renal  
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
16  
  
 
 impaired participants (N=6 mild renal impairment, N=6 moderate 
renal impairment, and N=6 severe renal impairment) as defined by 
[CONTACT_10495] (eGFR) (see Table 1 ). 
 
Six participants with normal renal function in each group (1A, 1B, 
1C) will be matched by [CONTACT_545], gender, age (± 10 years, but between 
18 to 85 years  of age),  and body mass  index (BMI) (18 to 40 kg/m2) 
at enrollment; eGFR ≥90 mL/min as  calculated  by [CONTACT_168716] (MDRD) to each renal impairment Group 2, 
3, and 4, respectively.  
Group 2: Severe renal  impairment: Stage  4 (eGFR  15-29 mL/min) 
and ESRD not on dialysis: Stage 5, MDRD (eGFR <15 mL/min). 
Group  3:   Mild   renal   impairment:  Stage   2,  MDRD (eGFR 
60-89 mL/min). 
Group 4: Moderate renal  impairment:  Stage  3, MDRD (eGFR 
30-59 mL/min). 
Number  of Sites:  [ADDRESS_196668]  or Intervention:  A single oral dose of pretomanid 200 mg  
Study  Objectives: Primary:  
• To evaluate the PK profiles of pretomanid in plasma and 
urine after a  single oral  dose of 200 mg in participants  with 
renal impairment compared to matched healthy controls.  
 
Secondary:  
• To assess the safety profile of a single oral dose of 200 mg 
pretomanid in renally impaired participants compared to 
matched healthy controls. 
• To evaluate the PK profiles of representative pretomanid 
metabolites (M19 and M50) in plasma and urine. 
Duration of Individual 
Participant  Participation:   
Approximately [ADDRESS_196669] 
Participant/Last Study  Day: Part A: 12 months  
Part B: 18 months  
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
18  
  
Table 1: Study  Design 
Part A  
Group  N Participant  Characteristics  Stagea eGFRb 
mL/min  
1A 6 Healthy  matched  participants  
(controls) with normal renal function N/A ≥[ADDRESS_196670]  
not on dialysis  4 
5 15-29 mL/min  
<15 mL/min  
Total  12 
 
Part  B 
Group  N Participant  Characteristics  Stagea eGFRb 
mL/min  
1B 6 Matched  participants  with normal  
renal  function N/A ≥90 
3 6 Mild  renal  impairment  2 60-89 
1C 6 Matched  participants  with normal  
renal  function N/A ≥90 
4 6 Moderate  renal  impairment  3 30-59 
Total  24 
CKD=chronic  kidney  disease;  eGFR=electronic case report  form;  ESRD=end  stage  renal  disease;  MDRD=Modification 
of Diet in Renal Disease; N/A=not applicable.  
a Stage  based on Clinical Practice  Guidelines  for CKD  (National  Kidney Foundation,  2002)  and Guidance  for Industry  
Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data analysis and Impact on Dosing 
(DHHS, FDA, and CDER 2020 Draft Guidance).  
b eGFR: estimated glomerular filtration rate based on an MDRD equation. Different mathematical formulas 
have been developed to determine eGFR. The MDRD eGFR formula was developed to adjust for body surface area 
and ethnicity,  as well as considerations  such as age and gender.  In many  ways  the MDRD  is superior to the Cockcroft - 
Gault calculation  as it is more precise and reliable in predicting GFR. eGFR for  this study  is automatically calculated 
by [CONTACT_168717].  
DMID  Protocol  15-0037  Version  11.0 
19  
 Renal Pharmacokinetics  11 April  2024  
Figure  1: Schematic  of Study Design  
 
ESRD=end  stage  renal  disease;  PK=pharmacokinetics  
Group  1A: Matched  controls  to Group  2, with normal renal  function 
Group 2: Severe renal impairment and ESRD, not on dialysis  
Group  1B: Matched  controls  to Group  3, with normal renal  function 
Group 3: Mild renal impairment  
Group  1C: Matched  controls  to Group  4, with normal renal  function 
Group 4: Moderate renal impairment  

DMID  Protocol  15-0037  Version  11.0 
20  
 Renal Pharmacokinetics  11 April  2024  
 
1 KEY ROLES  
 
 
 
Lead  Principal  Investigators:  William  Smith, MD 
Alliance  for Multispecialty  Research  (AMR) 
[ADDRESS_196671] 
Manager:  Erica  Sondergaard, RN, BSN, CCRC  
Statistical and Data 
Coordinating  Center:  The Emmes Company, LLC 
DMID  Protocol  15-0037  Version  11.0 
21  
 Renal Pharmacokinetics  11 April  2024  
 
2 BACKGROUND  INFORMATION AND SCIENTIFIC 
RATIONALE  
 
Background  
 
Tuberculosis 
 
Tuberculosis (TB) caused by [CONTACT_132284] (Mtb) is an age -old disease and remains 
a major public health  problem worldwide.  It is estimated  that one- third  of the world’s population is 
infected with Mtb, with about 10 million new cases of TB and 1.2 million deaths annually [ 1]. For 
the past 5 years,  TB has been  the leading cause of death  from a single infectious  agent,  ranking above 
HIV/AIDS [1]. Bacillus Calmette- Guérin (also known as BCG), an attenuated strain of 
Mycobacterium bovis , is the only available TB vaccine. The efficacy of this vaccine varies from 
place to place  and is  generally  low [2, 3]. However,  it is used  by [CONTACT_168718] [ 2, 3]. Therefore, TB control relies on case detection, 
chemoprophylaxis for newly infected individuals, and directly observed therapy short course 
(DOTS)  for TB patients.  DOTS,  despi[INVESTIGATOR_168679],  is not really  a short course.  Under DOTS,  patients 
are required  to take multiple  drugs for at least  6 months [ 4]. Similarly,  chemoprophylaxis for newly 
infected individuals takes 3 to 9 months [ 5, 6]. Long duration of treatment is associated with 
increased cost for follow -up, increased side effects of drugs and increased risk of default that may 
lead to emergence of drug-resistant  TB. The World  Health  Organization (WHO)  reports that several 
countries have large  numbers of  patients with  multidrug -resistant  tuberculosis (MDR -TB), resistant 
to at least isoniazid (INH) and rifampin  [7]. Further,  less than 50% of those  who  started  second -line 
drugs had successful  treatment outcome [1] and the number of  MDR- TB cases is  increasing  mainly 
due to lack of effective treatment [ 7]. In addition, several countries with high prevalence of MDR - 
TB also show  increasing  numbers of extensively drug- resistant  (XDR- TB) cases.  These  are resistant 
not only to INH and rifampin, but fluoroquinolones and aminoglycosides as well. Treatment of XDR- TB is even  more  difficult and the  outcome is unpredictable  [1, 8]. Thus, MDR- and XDR- TB 
are global problems because of the lack of effective treatment, the need for much longer treatment with second -line or experimental drugs, and the risk of further spread through travel and 
immigration. This calls for enhanced efforts to develop new drugs. 
Pretomanid  is approved by [CONTACT_168719] (US)  Food and Drug  Administration  (FDA)  and by [CONTACT_50743] (EMA) for treating adult patients with extensively drug- resistant, 
treatment- intolerant (TI) or nonresponsive (NR)  multidrug -resistant  pulmonary TB, in combination 
with bedaquiline (BDQ) and linezolid (LZD) (pretomanid, bedaquiline, and linezolid [BPaL] 
regimen). Pretomanid is administered orally 200 mg once daily for 26 weeks; the BPaL regimen is 
taken with food. 

DMID  Protocol  15-0037  Version  11.0 
22  
 Renal Pharmacokinetics  11 April  2024  
Tuberculosis in Patients  with  Renal  Impairment 
 
Chronic kidney disease (CKD) is defined as a reduced glomerular filtration rate (GFR), increased 
urinary albumin excretion, or both, for 3 or more months and is an increasing public health issue 
with estimated  prevalence of 8 to16% worldwide [9]. Patients with CKD and kidney transplant  have 
a higher risk  of developi[INVESTIGATOR_168680] [10-13] . Immunodeficiency associated with renal impairment appears to be 
multifactorial including defects in oxidative stress, inflammation, vitamin D deficiency, 
malnutrition, and functional abnormalities in immune cells, particularly B and T cells [ 11, 13]. 
Changes in immunity  begin as early  as Stage  3 CKD  (eGFR  30-59 mL/min/1.73 m2) and worsen  in 
later stages as kidney function deteriorates and waste products accumulate.  
The treatment of new drug-susceptible pulmonary TB in patients  with renal  impairment  includes 
[ADDRESS_196672] to be 
adjusted for renal function [ 14]. Approximately 80% of ethambutol is cleared by [CONTACT_168720]  [15, 16]. Pyrazinamide  is metabolized  in the liver 
and its metabolites such as pyrazinoic acid and 5-hydroxy- pyrazinoic acid may accumulate in 
patients  with renal  insufficiency  [15, 16]. Despi[INVESTIGATOR_168681]-line anti- TB drugs, patients 
with renal impairment have worse clinical outcomes than those without renal impairment, and 
require close monitoring [ 14, 17] . 
 
Pretomanid  
 
[IP_ADDRESS] Structure  and Molecular Weight  
 
Pretomanid, a nitroimidazooxazine,  is a chemical  entity  with a molecular  weight of 359 Daltons [18, 
19]. Figure 2 shows the chemical structure.  
Figure  2: Chemical  Structure of Pretomanid  
 

DMID  Protocol  15-0037  Version  11.0 
23  
 Renal Pharmacokinetics  11 April  2024  
[IP_ADDRESS] Mechanism  of Action  
 
The mechanism of action of pretomanid is not fully understood, but it appears to have multiple 
activities.  Under aerobic  conditions, it inhibits  Mtb cell wall biosynthesis by [CONTACT_168721] [ 20, 21]. Under anaerobic conditions, pretomanid generates 
reactive  nitrogen  species,  including nitric  oxide (NO)  [22]. These known mechanisms  under aerobic 
and anaerobic conditions explain why pretomanid has excellent early bactericidal and sterilizing 
activities [23, 24]. Early bactericidal activity (EBA) refers to an agent's ability to kill most of 
mycobacteria in the lung  during the first few weeks of treatment [ 23]. Sterilizing activity measures 
the ability of the drug to kill persisting forms of Mtb, and therefore decrease relapse rates [ 24, 25 ]. 
[IP_ADDRESS] Microbiologic  Activities in  Vitro  
 
In vitro  studies demonstrated that the pretomanid  was active against  actively  growing drug-sensitive 
Mtb isolates  with  the minimum  inhibitory concentration (MIC)  ranging from ≤0.0015 to 0.3 µ g/mL 
[20, 21], which  is comparable to the MIC  of INH,  one of the key first-line anti- TB drugs. Pretomanid 
was also tested in vitro against a broad panel of multidrug -resistant (MDR) clinical isolates of Mtb 
and was found to be highly active against  all tested  isolates  with MIC <1  µg/mL  [26]. Interestingly, 
in addition to its ability to kill actively growing Mtb, pretomanid demonstrated 85%, 89.6%, and 93.5% killing of Mtb persisting under anaerobic conditions at 2, 10, and 30 
µg/mL, respectively [ 26]. 
 
Pre-Clinical Animal Studies  
 
[IP_ADDRESS] Toxicology  
 
Before advancement to human trials, the potential adverse effects of pretomanid were evaluated in 
repeat -dose toxicity  studies up to 13 weeks in duration in mice,  up to 26 weeks in duration  in Sprague 
Dawley  rats, up to 13 weeks in duration in cynomolgus monkeys. Adverse effects  were  uncommon 
at doses ≤50mg/kg [ 18]. 
[IP_ADDRESS]
 Pharmacokinetics  
 
The PK profile of pretomanid following single -dose administration has been determined in mice, 
Sprague Dawley rats, cynomolgus monkeys, and New Zealand white rabbits, and the PK profile 
following repeated oral doses of pretomanid has been determined in Spr ague Dawley rats and 
cynomolgus monkeys [ 18]. Systemic exposure to pretomanid following a single oral dose in mice, 
rats, monkeys, and rabbits increased with increasing dose, but the increase was less than dose 
proportional. The elimination half -life (t ½) of pretomanid following a single oral dose was 
approximately 3 to 7 hours in male  rats, monkeys, and rabbits. The t½ in female  rats following single 
oral doses was longer (7 to 9 hours). In multiple  studies in rats, the time to peak  plasma concentration 
(Tmax) generally  ranged  from  3.3 to 8 hours. In 14-day studies in rats and monkeys, pretomanid levels  

DMID  Protocol  15-0037  Version  11.0 
24  
 Renal Pharmacokinetics  11 April  2024  
in plasma were comparable on Days 1 and 14, indicating no accumulation of pretomanid after 
repeated dosing. Elimination kinetics in rats, rabbits, and monkeys were comparable to values 
observed after  single doses,  suggesting sustained  pretomanid  exposure in  these animal  species does 
not induce drug metabolic systems or other means of eliminating the drug from the body. 
The elimination kinetics were determined in rats and monkeys using radiolabeled pretomanid 
preparations [18]. The findings suggest  that pretomanid is subjected  to both hepatic metabolism and 
renal  excretion. The majority  of the excretion  was into urine. An average of 88.1% and 67.5% of the 
dose was recovered in the urine and feces for rats and monkeys, respectively.  
[IP_ADDRESS] Efficacy  
 
In a dose fractionation study in a murine model of active TB, total pretomanid doses from 144 to 4608 mg/kg were  administered  as 3, 4, 8, 12, 24, or 48 divided doses over 24 days beginning 2 weeks 
after aerosol infection with Mtb [ 27]. In this model, pretomanid exhibited time -dependent 
bactericidal activity, with a maximum observed bactericidal effect of 0.1 log colony forming unit 
(CFU)/day over 24 days. Lung CFU counts strongly correlated with the free drug time above MIC (T>MIC)  and free drug area under the plasma concentration -time curve (AUC)/MIC,  where  T>MIC 
is the cumulative percentage of the dosing interval that the drug concentration exceeds the MIC under steady-state exposure conditions. 
The effectiveness of various 3 -drug combinations involving pretomanid was further evaluated in a 
murine  model  of TB. The combination of pretomanid  (50 mg/kg) with BDQ  and sutezolid  (SZD)  or 
LZD  was superior to that of the first -line regimen  for drug- susceptible TB (rifampin,  pyrazinamide, 
and INH in reducing lung mean CFU counts in BALB/c mice infected with Mtb. The addition of 
SZD  significantly  increased  the initial  bactericidal  activity  of pretomanid  + BDQ,  rendering all mice 
culture -negative between  1 and 2 months of treatment.  Although the decline in CFU counts with the 
3-drug regimen containing LZD was not as rapid as that for the regimen containing SZD, the 
combination of LZD + BDQ + pretomanid was also significantly superior to the standard regimen 
after 2 months of treatment [28]. Both 3- drug combinations (pretomanid + BDQ + [SZD or LZD]) 
resulted in significantly fewer relapses after [ADDRESS_196673]- line 
regimen or the 2-drug combination of pretomanid + BDQ. 
 
Clinical Trials for Safety and Pharmacokinetics  
 
[IP_ADDRESS] Safety  
 
Based on unpublished safety data of the Phase 1 pooling group (i.e., pooled data from all Phase 1 studies in healthy volunteers) from  the Integrated  Summary  of Safety  for the pretomanid  New Drug 
Application, the most  frequently (≥10%  of participants)  reported preferred  terms  of treatment -
emergent adverse events (TEAEs) in the all -pretomanid group (single dose or multiple doses) were  
headache (31.5%), nausea (11.8%), hemoglobin decreased  (10.7%), and dermatitis  

DMID  Protocol  15-[ADDRESS_196674] (11.4%). Hemoglobin decreased and dermatitis contact [CONTACT_168722]. Participants from all the treatment 
groups shared  the same trending with decreased  hemoglobin levels.  Dermatitis  contact  [CONTACT_168723] (ECG) patches. In the control group, the only AE reported in at 
least 10% of participants was headache, with an incidence lower than that in the all -pretomanid 
group (22.9% versus 31.5%). 
[IP_ADDRESS] Pharmacokinetics  
 
The Investigator  Brochure (IB) [18] includes data from the Phase 1 studies  in healthy volunteers and 
Phase 2 studies in participants with pulmonary TB. These data indicate that the PK profile for 
pretomanid following oral dosing was consistent for healthy participants and participants with pulmonary TB. In both populations, pretomanid was readily absorbed after oral administration and 
slowly eliminated from plasma. Pretomanid plasma concentrations increased in a dose-dependent 
manner after single -dose administration of up to 1000 mg in healthy participants and participants 
with TB, but the increase was  less than dose proportional, particularly at doses above 200 mg/day. 
The hypothesis that absorption decreases (i.e., is saturated)  at high doses of pretomanid  was further 
supported by [CONTACT_168724] (CL/F) and volume of distribution (V
d/F) 
at steady -state (Day  7) values increased  with dose, while  the mean  elimination  half-life (t1/2) values 
remained similar across dose levels. This suggests that the apparent lack of dose proportionality in exposure is most likely related to the decreased bioavailability with increasing dose. 
In both healthy participants and participants with pulmonary TB, steady- state concentrations of 
pretomanid in plasma were achieved within approximately 5 days of once -daily dosing, and the 
accumulation factor was approximately 2. Both findings support the observed elimination t
½ of 
approximately 18 hours in healthy participants  and participants with pulmonary TB. The mean  peak 
concentration  (C max) and AUC  from time  0 to 24 hours (AUC 0-24hr) values  following  a 200 mg dose 
of pretomanid in participants with pulmonary TB ranged from 1.1 to 1.2 μg/mL and 17 to 19 
μg·hr/mL, respectively, after single -dose administration and from 2.2 to 2.4 μg/mL and 38 to 40 
μg·hr/mL, respectively, after 14 days of dosing.  
Based  on the IB [18], pretomanid  is moderately  absorbed following  oral administration,  with a T max 
of 4 to 5 hours after single - or multiple -dose administration under fasted conditions. Dosing with a 
high- calorie, high- fat meal increased the T max by [CONTACT_3450] 1 hour, and the drug exposure was 
about half in the fasted  state comparing  with that in the fed state.  It is recommended  that the clinical 
dose of 200 mg be administered in the fed state. 
Overall, oral CL/F values (~8 L/hr) for pretomanid at a 200 mg dose are considerably less than the 
hepatic blood flow for a 70 kg human (1450 mL/min, 87.0 L/hr), suggesting that pretomanid is not highly extracted  by [CONTACT_4852].  Furthermore,  the apparent  V
d/F after a 200 mg dose was approximately  
DMID  Protocol  15-0037  Version  11.0 
26  
 Renal Pharmacokinetics  11 April  2024  
175 L, which is considerably higher than the total volume of body water (~42 L), indicating that 
pretomanid is distributed out of plasma. 
Pretomanid binding to human plasma protein is 86.4%, with the majority of the binding to human 
serum albumin [18]. In the presence of rifampi[INVESTIGATOR_2513] (strong cytochrome [CYP] 3A4 inducer) and 
efavirenz (moderate CYP3A4 inducer), pretomanid average concentration over a dosing interval 
(Cavg) is reduced  by 66% and 35%, respectively.  Therefore,  strong and moderate  CYP3A4  inducers 
should be avoided with pretomanid. 
Once -daily oral administration of pretomanid 400 mg for 14 days did not appear to significantly 
inhibit CYP3A4 in healthy participants, based on the results of a drug -drug interaction study with 
midazolam, a sensitive probe substrate for drugs metabolized by [CONTACT_097]3A enzymes. Results of in 
vitro  investigations using  human liver  microsomes also  support a low risk  of drug- drug interactions 
with pretomanid. In 2 mass -balance studies in healthy participants [18], approximately 91% of the 
administered  radioactive dose was recovered  in the urine (65%  and 53%) and feces (26% and 38%). 
The majority  of urinary  and fecal  radioactivity  elimination  occurred  within  [ADDRESS_196675]  of renal or hepatic impairment on the PK of pretomanid  is unknown.  
 
Efficacy  Studies  
 
[IP_ADDRESS] Efficacy  As a Single  Agent  
 
Different doses of pretomanid, given as a single agent, were evaluated in 2 studies [ 23, 29]. In the 
first study, doses of 200, 600, 1000, and 1200 mg/day were used [ 23]. In the second study, lower 
doses including 50, 100, 150, and 200 mg/day were  used [29]. Both studies produced a  measurable 
decrease in sputum CFU counts over the 14 -day treatment period. The results, summarized in  Table  
2, indicate that there were no meaningful differences among the pretomanid dose groups of 200 to 
1200 mg/day also supported by [CONTACT_168725]. There was a dose -related trend with 
respect to changes in mean logCFU values over time in the second study, with a smaller reduction 
seen in the 50 mg/day dose group compared  with the 100, 150, or 200 mg/day dose groups. This latter 
study, however, was not powered to detect significant differences between the dose groups.  

DMID  Protocol  15-0037  Version  11.0 
27  
 Renal Pharmacokinetics  11 April  2024  
[IP_ADDRESS] Efficacy  When  Administered  in a Multidrug  Regimen  
 
Three Phase 2 studies evaluated pretomanid efficacy in a multidrug regimen [18, 30-32] . The 
treatment regimens  studied, and results are summarized  in Table  2. The first multidrug  regimen  [30] 
compared 6 regimens:  
• BDQ  (alone).  
• BDQ + pyrazinamide.  
• pretomanid  + BDQ.  
• pretomanid  + pyrazinamide.  
• pretomanid  + moxifloxacin + pyrazinamide.  
• standard  treatment regimen  (INH,  rifampin,  pyrazinamide, and ethambutol). 
In this trial, the mean daily rate of decline in logCFU in the first [ADDRESS_196676] 
for pretomanid + moxifloxacin + pyrazinamide combination. The second multidrug regimen [32] 
was a 7 -arm study of the following treatments:  
• pretomanid  + BDQ + pyrazinamide + clofazimine.  
• pretomanid  + BDQ  + pyrazinamide.  
• pretomanid  + BDQ  + clofazimine.  
• BDQ  + pyrazinamide + clofazimine.  
• pyrazinamide  alone.  
• clofazimine  alone.  
• standard  treatment with INH,  rifampin,  and pyrazinamide.  
The study showed  that a regimen  containing pretomanid  + BDQ + pyrazinamide  resulted  in a marked 
daily rate of decline in logCFU (mean 0.167) comparable to standard treatment (mean  0.151), 
indicating that the pretomanid -containing regimen is a potential new TB treatment regimen. In the 
third  trial, 3 regimens were  compared, and the mean  daily  rate of decline of logCFU  with a regimen 
containing pretomanid 200 mg + moxifloxacin + pyrazinamide was significantly greater than standard treatment (0.155 vs 0.112, respectively) [31]. 
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
28  
  
[IP_ADDRESS] Efficacy  on Drug -Resistant  TB 
 
In a Phase 2 trial by [CONTACT_58119] [ 31], [ADDRESS_196677] -TB were treated with pretomanid + 
moxifloxacin + pyrazinamide. The mean daily rate  of decline in logCFU  over [ADDRESS_196678]  treatment  (0.117 vs 0.112, 
respectively). These results indicate that pretomanid is useful for treatment of MDR -TB. 
A Phase 3, pi[INVESTIGATOR_22735], open- label trial Nix -TB assessed the safety, tolerability, efficacy, and PK of 
BPaL regimen in the treatment of patients with either pulmonary XDR -TB or TI/NR MDR- TB. A 
total of [ADDRESS_196679] -TB or TI/NR MDR- TB were 
enrolled at 3 centers in South Africa. Patients received study treatment for a  minimum of 6 months 
(i.e., until Week 26). If patients were culture positive or reverted to being culture positive between 
Month [ADDRESS_196680] been extended to 9 months (i.e., Week 39) or the patient may have 
been  withdrawn  from the trial. The primary  endpoint was the incidence of an unfavorable outcome, 
defined as treatment failure (bacteriologic or clinical) or disease relapse. Clinical treatment failure 
was defined as a change from the protocol -specified TB treatment as a result of a lack of clinical 
efficacy, retreatment for TB, or TB -related death through follow -up until 6 months after the end of 
treatment. Th e success rate was 89%  at 6-month post end of  treatment. FDA  and EMA approval of 
pretomanid, in the context of the BPaL regimen, was based on the Nix- TB data [ 33]. 
Table  2:  Summary  of Phase  2 studies using  Pretomanid  
Outcome  
measure  N* Regimens  Results  Conclusions  Ref. 
Single  Agent  
Daily rate 
of decline 
in logCFU 
over 14 
days (Mean  
± SD) 69 Pretomanid  200 mg 0.098  ± 0.07 Outcome measure the same 
for all 4 pretomanid  dosages.  [23] 
Pretomanid  [ADDRESS_196681]  (HRZE)¥ 0.148  ± 0.055  
Daily rate 
of decline 
in logCFU 
over 14 days (Mean  
± SD) 69 Pretomanid  50 mg 0.063  ± 0.058  -Dose -related trend with a 
smaller reduction seen in the 
50 mg/day group.  
-Study  not powered  to detect 
significant differences  
between  the dose groups.  [29] 
Pretomanid  100 mg 0.09 ±  0.073  
Pretomanid  150 mg 0.078  ± 0.074  
Pretomanid  200 mg 0.112  ± 0.[ADDRESS_196682]  (HRZE)¥ 0.177  ± 0.042  
Multidrug  Regimen  
Daily rate 
of decline in logCFU 
over 14  85 Bedaquiline  0.061  ± 0.068  -The mean  decline  in CFU  in 
pretomanid + moxifloxacin + 
pyrazinamide group was significantly higher than the decline in all other groups  [30] 
Bedaquiline  + 
pyrazinamide  0.131  ± 0.102  
Pretomanid  + 
Bedaquiline  0.114  ± 0.050  
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
29  
  
 
Outcome  
measure  N* Regimens  Results  Conclusions  Ref. 
days (Mean  
± SD)  Pretomanid  + 
Pyrazinamide  0.154  ± 0.040  except pretomanid + 
pyrazinamide and standard 
treatment groups.   
Pretomanid + 
Moxifloxacin  + 
Pyrazinamide  0.233  ± 0.[ADDRESS_196683]  (HRZE)¥ 0.14 ±  0.094  
Daily rate 
of decline 
in logCFU 
over 14 days,  Mean 
(95% CI) 105 Pretomanid + 
Bedaquiline + Pyrazinamide  + 
Clofazimine  0.115  
(0.039- 0.189)   [32] 
Pretomanid + 
Bedaquiline  + 
Pyrazinamide  0.167  
(0.075- 0.257)  This regimen  is a potential 
new TB treatment.  
Pretomanid  + 
Bedaquiline  + 
Clofazimine  0.076  
(0.005- 0.145)   
Bedaquiline  + 
Pyrazinamide  + 
Clofazimine  0.124  
(0.035- 0.214)   
Pyrazinamide  0.036  
(-0.026- 0.099)   
Clofazimine  -0.017  
(-0.085 -0.053)  Clofazimine  has no activity  
alone.  
Standard  (HRZE)¥ 0.151  
(0.071- 0.232)   
Daily rate 
of decline 
in logCFU 
over 56 days,  Mean 
(95% 
Bayesian 
credibility 
interval)  207 Pretomanid  (100 mg) 
+ Moxifloxacin + 
Pyrazinamide  0.133  
(0.109- 0.155)   [31] 
Pretomanid  (200 mg) 
+ Moxifloxacin + 
Pyrazinamide  0.155  
(0.133- 0.178)  -Daily  CFU  decline  
significantly greater than that 
for standard treatment.  
Standard  (HRZE)¥ 0.112 (0.093 - 
0.131)   
Pretomanid  (200 mg) 
+ Moxifloxacin + 
Pyrazinamide  0.117 (0.070 - 
0.174)  -Only  MDR -TB patients 
included.  
-Daily reduction in CFU was comparable to that of standard 
treatment for patients with drug-susceptible TB. 
CI=confidence interval; CFU=colony forming unit; HRZE=standard treatment with isoniazid, rifampin,  pyrazinamide, 
and ethambutol; MDR -TB=multidrug -resistant tuberculosis; TB=tuberculosis.  
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
30  
  
 
*N includes all volunteers randomized to the different study groups. ¥, Standard (HRZE) indicates standard treatment 
with isoniazid, rifampin, pyrazinamide, and ethambutol.  
§All pretomanid doses were once daily and all -pretomanid doses were [ADDRESS_196684] 6 months [ 4]. New drug treatments may help shorten the 
duration of treatment  and potentially increase patient compliance,  and therefore,  have  a direct impact 
on the control of TB. Furthermore, MDR and XDR -TB have made the prevalence of TB more 
challenging. Up to 50% of MDR -TB cases fail treatment and treatment outcome of XDR -TB is 
unpredictable [1], indicating that development of new anti -TB drugs is an essential component of 
TB control. 
Pretomanid  is one of a few anti -TB drugs  with the following unique and attractive characteristics:  
 
1. It has early  bactericidal  and sterilizing  activity,  with a potential to shorten the duration  of 
treatment for drug -susceptible TB [ 23, 24]. It shortens the duration of treatment for 
MDR-TB in the context of the BPaL regimen [ 33], 
2. It has excellent  activities  against  both drug- sensitive and MDR- isolates  of Mtb [ 26], 
3. It has been  shown to have a low incidence of AEs  in multiple  clinical trials [18], 
4. It has narrow spectrum of activity limited primarily to Mtb with no significant activity 
against a broad range of Gram -positive and Gram- negative bacteria [ 34], 
5. It has no demonstrable cross  resistance  to a variety  of anti-TB drugs [ 25], 
6. It is administered  orally [18, 19], and 
7. It neither inhibits nor is metabolized by [CONTACT_168726]450 enzyme isoforms except for 
CYP3A4 in vitro, importantly indicating a low potential for drug -drug interactions, 
including with presently used antiretrovirals for treatment of HIV [ 35, 36] . 
Patients with renal impairment, particularly severe renal impairment or end stage renal disease 
(
ESRD),  may have an  increased  risk of drug exposure and may require lower  doses of certain  drugs 
compared to patients with normal renal function [ 37]. According to FDA and Europe, the Middle 
East,  and Africa  (EMEA)  guidelines, a PK study should be carried  out during the development phase 
of a new drug that is likely  to be used in patients  with renal  dysfunction and whose pharmacokinetics 
are likely  to be significantly  altered  in renally  impaired  patients  [38, 39]. Less than 1% of 

DMID  Protocol  15-0037  Version  11.0 
31  
 Renal Pharmacokinetics  11 April  2024  
unmetabolized pretomanid is excreted in the urine. [ 18]. Therefore, like other commonly used  anti-
TB drugs such as ethambutol and pyrazinamide, which are at least partly eliminated through kidneys,  
the PK of pretomanid  must  be studied  in patients with CKD.  CKD is a very common clinical disease 
with estimated prevalence of 8 to 16%, and CKD patients globally, particularly those in advanced 
stages, have significantly increased risk of developi[INVESTIGATOR_168682] [ 11-13] . 
Regarding pretomanid metabolites, no single metabolic pathway can be considered major. Two metabolites  have been  selected  for quantification: M19 (4-Trifluoromethoxybenzoic acid)  and M50 
(hydroxy imidazole). In one mass -balance study, M19 was the largest drug- derived metabolite, 
representing up to 35% of the sample  radioactivity  at [ADDRESS_196685]-dose. However,  it has no activity 
or toxicity. In another mass -balance study, M50 was found to account for 6.3% of the parent area 
under the AUC  and it has been  identified  as potentially  genotoxic based  on an in vitro  Ames  test. In 
2 mouse genotoxicity studies,  no genotoxicity was observed up to a 2000 mg/kg dose. In a recently 
completed carcinogenicity study in transgenic mice with M50 exposure 2- [ADDRESS_196686] been found to represent more than 13% of the total dose  in urine and feces.  Therefore,  based  on results  from previous studies and 
expected excretion in urine, measuring the plasma exposures of pretomanid metabolites (M50 and M19) in this patient population will be valuable.  
The results from this study will help determine future dosing and frequency of administration of 
pretomanid that can be safely used in patients with different stages of renal impairment.  
 
Study Population  
 
The study population will be  representative of participants with varying degrees of renal disease as 
defined by [CONTACT_168727]. Children will not be 
included as this study is designed for adult participants between  the ages of 18-85 years  (for detailed 
information see Section 5.1 Eligibility Criteria).  
 
Potential  Risks and Benefits  
 
Potential Risks  
 
The potential risks of this trial are those associated with having blood drawn, adverse reactions to 
pretomanid, and breach of confidentiality. 
Potential adverse drug reactions include mild to moderate nausea and vomiting, mild to moderate 
rash, and increased transaminases. These are listed as adverse drug reactions in the pretomanid IB [18]. 

DMID  Protocol  15-0037  Version  11.0 
32  
 Renal Pharmacokinetics  11 April  2024  
In pooled Phase 1 trials (i.e., pooled data from all Phase 1 studies in healthy volunteers) where 
pretomanid  was dosed as single or multiple  doses,  the most frequently observed AEs were  headache 
and nausea.  
A study on the effects of pretomanid in healthy volunteers determined that increases in creatinine 
were noted at high repeat doses in healthy volunteers. A follow -up intensive renal function study 
revealed that the drug does not adversely affect GFR, renal plasma flow, or filtration fraction but appeared  to decrease tubular renal  secretion  of creatinine.  A single dose of pretomanid  did not affect 
kidney function in healthy  participants  and it is not anticipated  that kidney function will change from 
a single dose. 
Testicular toxicity is considered as a potential risk based on pre- clinical studies. TB Alliance is 
currently  conducting a study to further investigate pretomanid  and testicular toxicity.  A single dose 
of pretomanid is however, not anticipated to have an impact on testicular function in general.  
After administering the pretomanid, patients will be closely observed and asked about any new 
symptoms before each blood draw.  Clinical evaluation will be done when  necessary,  during the first 
[ADDRESS_196687] procedures will be followed. Volunteers with serious side effects identified during the follow -up 
visits will be transported to the Emergency Department (ED) of the local hospi[INVESTIGATOR_168683]. 
To limit possible adverse reactions to study participants, volunteers who donated blood or blood 
products >500 mL within 30 days from screening or who plans to donate during the study or up to 
14 days after dosing will be excluded from the study. 
Blood Draw  
 
Drawing blood may cause transient discomfort and fainting. Fainting is usually transient and 
managed  by [CONTACT_168728]/her legs. Bruising at the blood  draw site 
may occur but can be prevented or lessened by [CONTACT_119911] a few minutes after the blood is taken. Rarely,  drawing blood may cause infection  (thrombophlebitis).  The 
use of aseptic (sterile) technique will make infection  at the site where  blood will be drawn  extremely 
unlikely.  
Peripheral  Catheter  (if needed)  
 
Inserting a peripheral catheter may cause pain, bleeding, hematoma, vein irritation, infiltration, extravasation, phlebitis, air embolism, and/or infection. Use of proper aseptic technique during the 
insertion provides protection against infection.  
DMID  Protocol  15-[ADDRESS_196688] agree to use an effective method of birth 
control for the duration of the study ( Section  5.1.1).  Males who are sexually active with a female  of 
childbearing potential must  agree  not to father a child  or donate sperm  for the duration of the study.  
Other  Risks  
 
Personal Health  Information  (PHI) 
 
Participants will be asked to provide PHI. All attempts will be made to keep this PHI confidential 
within the limits of the law. However, there is a chance that unauthorized persons will see the 
participants’ PHI. All study records will be kept in a locked  file cabinet or maintained in a locked 
room at the participating sites. Electronic files will be password -protected. Only people who are 
involved in  the conduct, oversight, monitoring, or auditing of this trial will  be allowed  access to  the 
PHI that is collected. Any publications from this trial will use de -identified information. 
Organizations  that may inspect and/or copy research  records  maintained  at the participating  site for 
quality assurance and data analysis include groups such as the local Institutional Review Boards 
(IRBs), National Institute of Allergy and Infectious Diseases (NIAID), and FDA.  
As required by [CONTACT_20008], a description of this clinical trial will be available on https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]. This website will not include information  that can 
be used to identify participants. At most, this website will include a summary of the results.  
There  may be other risks, discomforts, or side effects that are  unknown at this time.  
 
Potential Benefits  
 
There  is no direct benefit  to participants  who will receive the study product. This study is a PK study 
in patients with renal impairment. Patients with renal impairment have a higher risk of developi[INVESTIGATOR_168684]. The results from this 
study will help determine the safe and effective dose of pretomanid for treatment of TB in patients with renal  impairment.  Pretomanid, in the context  of the BPaL  regimen,  shortens the treatment  of TI 
or NR MDR and XDR-TB to 6 months. 

DMID  Protocol  15-0037  Version  11.0 
34  
 Renal Pharmacokinetics  11 April  2024  
 
3 STUDY  DESIGN,  OBJECTIVES,  AND  ENDPOINTS  OR 
OUTCOME MEASURES  
 
Study Design  Description 
 
This is a Phase 1, open -label, single -dose, sequential group study to evaluate the PK and safety 
profile of pretomanid in participants with renal impairment (excluding those with ESRD needing 
dialysis) compared to matched participants with normal renal function. 
The study will be conducted following a reduced PK study design in Part A, see Table  1 and Figure 
1. Part A will enroll participants from Group 1A (i.e., 6 healthy matched controls) and Group 2 (i.e., 
[ADDRESS_196689], not on dialysis).  
A decision to proceed to Part B will be made after the PK of pretomanid and safety of participants 
enrolled in Part A have been  reviewed. If Part A demonstrates at least a 50% increase in pretomanid 
AUC in Group 2 (severe renal impairment and ESRD, not on dialysis) relative to the exposures in Group 1A (matched  participants  with normal renal  function), then the reduced  PK study  will extend 
to the full PK study to enroll participants into Part B (i.e., to investigate mild and moderate renal impairment) and all enrollment will be initiated concurrently in Part B groups (1B, 1C, 3, and 4). 
Otherwise, no further study is recommended.  
Study  Population 
Part A  
Group 1A: 6 healthy participants  (matched  controls) with normal renal  function: MDRD (eGFR  
≥90 mL/min).  Participants  will be matched  by [CONTACT_545],  gender, age (± 10 years,  but between  18 to 
85 years of age) and body mass index (BMI) (18 to 40 kg/m
2). 
Group 2: 6 severe renal  impairment participants:  Stage  4, MDRD (eGFR  15-29 mL/min),  and ESRD 
not on dialysis, Stage 5, MDRD (eGFR <15 mL/min). 

DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
35  
  
Part  B 
 
Groups  1B and 1C : 6 healthy  participants  (matched  controls) each,  for Groups 3 and 4, respectively: 
MDRD (eGFR ≥90 mL/min). Participants will be matched by [CONTACT_545], gender, age (± 10 years, but 
between 18 to 85 years of age) and BMI (18 to 40 kg/m2). 
Group 3: 6 mild renal impairment participants:  Stage  2, MDRD (eGFR  60-89 mL/min).  
 
Group 4: 6 moderate renal impairment participants: Stage  3, MDRD (eGFR 30 -59 mL/min).  
 
Study Objectives  
 
Primary  
 
• To evaluate the PK profiles  of pretomanid  in plasma  and urine  after a single  oral dose of 200 mg 
in participants with renal impairment compared to matched healthy controls.  
 
Secondary  
 
• To assess the safety  profile  of a single  oral dose of 200 mg pretomanid in renally  impaired 
participants to matched healthy controls.  
• To evaluate the PK profiles  of representative pretomanid metabolites (M19  and M50) in plasma 
and urine. 
 
Study Endpoints or Outcome Measures  
 
Primary  
 
[IP_ADDRESS] Plasma  PK of Pretomanid  (see Section 10.5 for specific PK parameters)  
 
The plasma PK  of a single  dose of pretomanid  will be assessed  from serial  blood samples collected 
up to 1 hour pre-dose (Day  1) and at multiple  time points post dosing: 1, 2, 4, 5, 6, 8, 12, 16, 24, 36, 
48, 72, and 96 hours. The primary outcome measure will be total plasma concentration of 
pretomanid.  
[IP_ADDRESS] Urine  PK of Pretomanid (see Section 10.5 f or specific PK parameters)  
 
The urine PK of a single dose of pretomanid will be assessed from urine collected up to [ADDRESS_196690] -dose. Volume of urine will be 
measured and recorded at each of these time intervals. Urine samples will be stored at room 
temperature and then frozen at - 20°C within 24  hours. Urine samples will be stored in ≤100 mL 
aliquots at -20°C until shipped to Fisher Bioservices for storage. 

DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
36  
  
 
 
The concentrations of pretomanid in plasma and urine will be measured by [CONTACT_168729]. The pretomanid PK profiles  in plasma and urine  estimated  through a 
non-compartmental analysis.  
 
Secondary  
 
• Safety  – Number of participants  reporting AEs.  (Time  Frame: Time  of dosing [Day  1] to 
Day 12). 
• Safety – Mean change from baseline in hemoglobin (Hgb), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), total bilirubin, blood urea nitrogen (BUN), creatinine 
(includes eGFR), serum potassium and magnesium (Time Frame: Screening [Days  -28 to - 7], 
Day 5 and Day 12). 
• Safety  – Mean  change from  baseline in oral temperature,  pulse, and sitting  blood pressure (Time 
Frame: Day 1 [pre -dose], 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, and Day 12). 
• Safety – Mean change  from  baseline in ECG corrected  QT interval by [CONTACT_6550]  (QTcF)  (Time 
Frame: Screening [Days -28 to -7] and Day 5). 
• The concentrations of pretomanid metabolites (M19 and M50) in plasma will be measured by 
[CONTACT_168730]. PK – area under the plasma concentration- time curve  from time 
[ADDRESS_196691] measurement (AUC last), and any other parameters considered to be of interest, of 
representative metabolites M19 and M50 in plasma (Time Frame: Up to [ADDRESS_196692]-dose). 
• Excretion of representative metabolites M19 and M50 in urine. The amounts of M19 and M50 will be calculated in urine (i.e., M19 and M50 concentrations measured using validated bioanalytical methods multiplied by [CONTACT_168731]).  

DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
37  
  
4 STUDY INTERVENTION/INVESTIGATIONAL  PRODUCT  
 
Study Product Description  
 
Pretomanid, a nitroimidazooxazine, is a novel TB treatment that is being investigated for use with 
other TB drugs to shorten and/or simplify regimens to treat either drug- susceptible or resistant 
disease, which may improve the current high rate of noncompliance for TB t reatment. Pretomanid 
acts by [CONTACT_168732], as well as generating NO.  
 
Formulation,  Packaging, and Labeling  
 
For this study, pretomanid 200 mg tablets are white to off-white, oval- shaped tablet debossed with 
M on one side and P200. The formulation of pretomanid tablets is summarized in Table 3 . 
Table  3: Pretomanid  Formulation  
Ingredient  % Weight per  Unit (mg)  
Pretomanid,  Micronized  25.0 200.0  
Lactose  Monohydrate  NF (Foremost  FastFlo  316) 36.8 294.4  
Microcrystalline  Cellulose  NF (Avicel  PH102)  29.4 235.2  
Sodium  Starch  Glycolate  NF (Explotab)  5.0 40.0 
Magnesium  Stearate  NF (Hyqual)  1.0 8.0 
Colloidal  Silicon  Dioxide  NF (Cab -O-Sil M-5P) 0.3 2.4 
Sodium  Lauryl  Sulfate  USP 0.5 4.0 
Povidone  USP (PVP K30)  2.0 16.0 
Purified  Water  USP -- -- 
Total  100%  800.0 mg 
NF=National  Formulary;  USP=United  States  Pharmacopeia. 
Note: Water is removed during drug product manufacture.  
TB Alliance  or its designee will package the study  product. Study product will be labeled  and 
supplied according to applicable regulatory requirements.  
 
 
Product  Storage and Stability  
 
The investigator or an approved designee (e.g., pharmacist) will ensure that the study  product is 
stored  in a locked, secure area (with  access limited  to authorized  study  personnel only) under  

DMID  Protocol  15-0037  Version  11.0 
38  
 Renal Pharmacokinetics  11 April  2024  
recommended  storage conditions and in accordance with applicable  regulatory  requirements.  
Pretomanid will be stored at 15 -30°C (59-86°F). 
 
Acquisition/Distribution 
 
Pretomanid will be provided by [CONTACT_168733].  
Upon request by [CONTACT_168734] (DMID), pretomanid will be 
transferred to the following address: 
DMID Clinical  Materials  Services Contract 
Fisher BioServices  
[ADDRESS_196693] 
Germantown, MD [ZIP_CODE] 
Phone: 240-477- 1350  
Fax: 240- 477-1360  
Email: [EMAIL_1395]  
 
All study products (i.e., pretomanid) will be shipped  to the participating  sites prior to the start of this 
study upon request and with prior approval from DMID. Should the site principal investigator (PI) 
require additional study product during this trial, further instructions are provided in the protocol -
specific manual of procedures (MOP).  
 
Dosage/Regimen,  Preparation,  Dispensing,  and Administration of 
Study Intervention/Investigational Product 
Pretomanid will be administered in the fed state in this study because there is a food effect for the drug. Following an overnight fast of at least 8 hours, participants  should start the recommended  meal 
prior to administration  of pretomanid  [40]. Study participants  should eat this meal  in 30 ± 10 minutes 
or less; however, pretomanid should be administered 30 ± [ADDRESS_196694]-dose. If 
a participant vomits >[ADDRESS_196695].  

DMID  Protocol  15-0037  Version  11.0 
39  
 Renal Pharmacokinetics  11 April  2024  
 
Pre-determined  Modification of Study  Intervention/Investigational 
Product for an Individual Participant  
Since  a single oral dose of pretomanid will be given, there will be  no dose modifications.  
 
Accountability Procedures for the Study Intervention/ Investigational 
Product(s) 
Pretomanid will be sent to the DMID Clinical Materials Services (CMS) contractor, and then 
supplied to  the participating  sites prior  to the start of the study. Should the site PI [INVESTIGATOR_168685], further instructions  are provided in the protocol- specific MOP.  
After receipt of pretomanid, the site  PI [INVESTIGATOR_168686]. The  site PI [INVESTIGATOR_168687]’s research pharmacist responsibility for study product accountability. The site research 
pharmacist will be responsible for maintaining  complete  records and documentation of study product 
receipt, accountability, dispensation, storage conditions, and final disposition of the study product. For this study, all study product, pretomanid tablets, should be stored at 15- 30°C (59- 86°F) in blister -
strips comprising a thermoformable -film a nd a lidding foil configuration. All doses of pretomanid, 
whether administered or not, must be documented on the appropriate study product accountability record or dispensing log. The sponsor's monitoring staff will verify the participating sites’ study 
product accountability records and dispensing logs per the site monitoring plan. 
Unused tablets should be retained within the container in which they are supplied from the CMS. 
Unused pretomanid tablets will be monitored  and released  for final disposition. Final  disposition of 
the pretomanid will be determined by [CONTACT_168735].  

DMID  Protocol  15-0037  Version  11.0 
40  
 Renal Pharmacokinetics  11 April  2024  
 
5 SELECTION  OF PARTICIPANTS  AND STUDY 
ENROLLMENT AND WITHDRAWAL  
The study population will be represented by [CONTACT_168736]. Part A will enroll participants into Groups 1A (i.e., 6 healthy matched controls) 
and 2 (i.e., [ADDRESS_196696], not on dialysis).  
In this study, participants with renal impairment will be mainly identified from sites’ exhaustive database and through referral from local renal clinics. Non -renally impaired participants will be 
identified from participants who have previously participat ed in clinical trials and through the 
community.  
The decision to proceed from Part A to Part B will be made jointly by [CONTACT_168737]. An independent safety review will be carried out by [CONTACT_45000]  (SMC)  and the DMID Medical  Monitor. This review  will inform the decision to proceed 
from Part A to Part B.  
Part B will be conducted only if the Part A results demonstrate that participants with severe renal impairment and ESRD (not on dialysis) have different exposures to pretomanid that may impact 
safety  or efficacy  relative  to the exposures of healthy participants.  If no difference in PK is observed 
in Part A, then no further study (Part B) will be recommended.  
If the decision is made to conduct Part B, 12 participants (6 participants in each group) with mild 
and moderate renal  impairment will be enrolled  in Groups 3 and 4, respectively,  along with 12 
healthy matched participants (Groups  1B and 1C). Participants in Part B will receive the same single 
[ADDRESS_196697] be assessed by a study clinician licensed to make 
medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637] -investigator. 
No exemptions are granted for participant inclusion or exclusion criteria in DMID -sponsored 
studies. Questions about eligibility will be directed to the DMID Medical Officer.  
 
Eligibility  Criteria  
 
Participant  Inclusion Criteria  
 
[IP_ADDRESS] Participant  Inclusion Criteria  for Patients  with  Renal  Impairment  (Groups  2-4) 
 
Participants  eligible  to participate  in this trial must meet  all of the following  inclusion criteria: 

DMID  Protocol  15-[ADDRESS_196698]  no history  of chronic tobacco/nicotine usage (i.e., >10 cigarettes per day for 3 months 
minimum prior to admission).  
6. Have  QTc interval <[ADDRESS_196699]  a BMI  of 18 to 40 kg/m2 at enrollment.  
8. Women  of childbearing potential2 must  use an acceptable contraception  method3 for the duration 
of the study. 
2Not sterilized via tubal ligation, bilateral oophorectomy, bilateral salpi[INVESTIGATOR_1656], hysterectomy, 
implanted contraceptive device placement (permanent, non -surgical, non- hormonal sterilization) with 
documented  radiological  confirmation test at least  90 days after  the procedure,  and still menstruating  or 
<[ADDRESS_196700], barrier methods such as condoms with spermicide or diaphragms/cervical caps with spermicide, effective intrauterine devices, NuvaRing®, and licensed 
hormonal methods such as implants, injectables, or oral contraceptives (“the pi[INVESTIGATOR_4382]”).  
9. If participant  is male  and capable of reproduction, agrees to avoid fathering  a child  for the 
duration of the study by [CONTACT_168738]4. 
4In addition to the use of a barrier method (condom) unless vasectomized, acceptable methods of birth 
control are restricted to a monogamous relationship with a woman who agrees to use acceptable 
contraception as outlined in inclusion criterion #8, and/or abstinence from sexual intercourse with 
women.  
10. Women  of childbearing potential must  have a negative urine pregnancy test within  [ADDRESS_196701]. 
[IP_ADDRESS] Pa rticipant  Inclusion  Criteria  for Healthy Participants  (Groups  1A-1C) 
 
Healthy  participants  eligible  to participate  in this trial must meet  all of the following inclusion 
criteria: 
DMID  Protocol  15-[ADDRESS_196702] provided written  informed 
consent1 before any study- related procedure is performed.  
1As evidence by [CONTACT_168739]. 
 
2. Agree  to abide by [CONTACT_168740].  
3. Are healthy male or non-pregnant female, between the ages of 18 and 85 years, inclusive, with 
normal GFR >[ADDRESS_196703]  no history  of chronic  tobacco/nicotine usage (i.e., >10 cigarettes per day for 3 months 
minimum prior to admission).  
5. Have  a normal QTc interval <[ADDRESS_196704]  a BMI  of 18 to 40 kg/m2 at enrollment.  
7. Women  of childbearing potential2 must  use an acceptable contraception  method3 for the duration 
of the study. 
2Not sterilized via tubal ligation, bilateral oophorectomy, bilateral salpi[INVESTIGATOR_1656], hysterectomy, 
implanted contraceptive device placement (permanent, non -surgical, non- hormonal sterilization) with 
documented  radiological  confirmation test at least  90 days after  the procedure,  and still menstruating  or 
<[ADDRESS_196705], barrier methods such as condoms with spermicide or 
diaphragms/cervical caps with spermicide, effective intrauterine devices, NuvaRing®, and licensed 
hormonal methods such as implants, injectables, or oral contraceptives (“the pi[INVESTIGATOR_4382]”).  
8. If participant  is male  and capable of reproduction, agrees to avoid fathering  a child  for the 
duration of the study by [CONTACT_168738]4. 
4In addition to the use of a barrier method (condom) unless vasectomized, acceptable methods of birth 
control are restricted to a monogamous relationship with a woman who agrees to use acceptable contraception as outlined in inclusion criterion #7 , and/or abstinence from sexual intercourse with 
women.  
9. Women  of childbearing potential must  have a negative urine pregnancy test within  [ADDRESS_196706]. 
 
Participant  Exclusion Criteria  
 
[IP_ADDRESS] Participant  Exclusion Criteria  for Patients  with  Renal  Impairment  (Groups  2-4) 
 
Participants  eligible  to participate  in this trial must  not meet  any of the following exclusion criteria: 
 
1. History  of known active TB.  

DMID  Protocol  15-0037  Version  11.0 
43  
 Renal Pharmacokinetics  11 April  2024  
2. History  of peptic  ulcer disease.  
3. Known  hypersensitivity  to pretomanid  or any of the excipi[INVESTIGATOR_840].  
4. History  of any clinically significant  uncontrolled cardiac abnormality  (as deemed  by [CONTACT_978]). 
5. Any clinically  significant  ECG abnormality  at screening1. 
 
1Note:  the following  can be considered  not clinically  significant:  
 
• Heart rate < 50 beats per minute (bpm) (sinus bradycardia with heart rate between 45 and 49, 
inclusive, is acceptable only in younger athletic participants, as determined by [CONTACT_978])  
• Mild  first-degree atrioventricular  (A-V) block  (P-R interval  >0.23 seconds)  
• Right or left axis deviation  
• Incomplete right  bundle  branch block  
• Isolated  left anterior  fascicular  block  (left anterior  hemiblock)  in younger  athletic  participants 
6. History  of, or screening results show a QTc  interval ≥460 msec.  
7. Family  history  of Long- QT Syndrome or sudden death when a cause of death is unknown.  
8. Inability  to swallow  tablets.  
9. History of fever or documented fever (oral temperature > 100.4°F) in the 48 hours prior to 
admission to the hospi[INVESTIGATOR_307]. 
10. Resting  pulse rate <50  or >110 bpm at Screening.  
11. At Screening, blood pressure >20 mm Hg systolic or >10 mm Hg diastolic above baseline2 
(sitting).  
2Baseline  is most  recent blood pressure  in the last 3 months.  
 
12. Current hyperkalemia or hypomagnesemia. 
13. Positive result of urine drug screen or alcohol screen prior to hospi[INVESTIGATOR_168688]. 
14. Significant history  of drug and/or food allergies  (as deemed  by [CONTACT_978]). 
15. For women, participant is pregnant (positive test for urine Human Chorionic Gonadotropin [HCG]) at screening or Admission, breastfeeding, or planning to conceive for  the duration of 
the study. 
16. Any contraindication to the use of nitroimidazoles, or prior treatment with pretomanid or 
delamanid.  
17. Treatment with strong or moderate CYP3A4 inducers or inhibitors
3 within 14 days before 
admission and during the study4. 
DMID  Protocol  15-0037  Version  11.0 
44  
 Renal Pharmacokinetics  11 April  2024  
 
3Except hormonal  contraceptives 
 
4In the opi[INVESTIGATOR_168689]: See Table  [ADDRESS_196707] of drugs  known to alter  the function  of CYP3A4  (Section  7.1.1 ). 
 
18. Use of St. John’s Wort within  7 days prior to admission and during the entire  study. 
19. Consumption of products containing grapefruit  within  5 days prior to dosing until Visit  01N. 
20. Donation of whole blood or blood products >500 mL within 30 days from screening and/or 
plans to donate during the study or up to [ADDRESS_196708] study visit.  
22. Hgb <8.0 g/dL in both men and women  at the screening visit.  
23. Positive  Screening test for hepatitis  C virus (HCV),  hepatitis  B virus (HBV),  or HIV.  
24. Renal  transplant.  
25. Scheduled for hemodialysis or peritoneal dialysis.  
26. Presence  of any condition or finding5 which  would jeopardize  participant  safety,  impact  study 
result validity, or diminish the participant’s ability to undergo all study procedures and 
assessments.  
5In the opi[INVESTIGATOR_871] 
 
27. For men, semen donation for the duration of the  study.  
28. AST  and ALT > 2.5 x upper limit of normal (ULN).  
29. Hyperbilirubinemia  >1.[ADDRESS_196709].  
 
[IP_ADDRESS] Participant  Exclusion Criteria  for Healthy Participants  (Groups  1A-1C) 
 
Participants  eligible  to participate  in this trial must  not meet  any of the following exclusion criteria: 
 
1.
 History  of known active TB.  
2. History  of peptic  ulcer disease.  
3. Known  hypersensitivity  to pretomanid  or any of the excipi[INVESTIGATOR_840].  
4. History  of any clinically significant  uncontrolled cardiac abnormality  (as deemed  by [CONTACT_978]). 
5. Any clinically  significant  ECG abnormality  at screening.1 
 
1Note:  the following  can be considered  not clinically  significant:  
DMID  Protocol  15-0037  Version  11.0 
45  
 Renal Pharmacokinetics  11 April  2024  
 
• Heart  rate < 50 bpm (sinus  bradycardia with heart  rate between  45 and 49, inclusive,  is acceptable 
only in younger athletic participants)  
• Mild  first-degree A-V block  (P-R interval  >0.23 seconds)  
• Right or left axis deviation  
• Incomplete right  bundle  branch block  
• Isolated  left anterior  fascicular  block  (left anterior  hemiblock)  in younger  athletic  participants 
6. Family  history  of Long- QT Syndrome or sudden death when a cause of death  is unknown.  
7. Inability  to swallow  tablets.  
8. History  of fever  or documented fever  (oral temperature  >100.4°F) in the 48 hours prior to 
admission to the hospi[INVESTIGATOR_307]. 
9. At Screening  blood pressure >140/90 mm Hg or <90/65 mm Hg (sitting).  
10. History  of, or screening  results show a QTc interval  ≥460 msec.  
11. Positive result of urine drug screen or alcohol screen prior to hospi[INVESTIGATOR_168688]. 
12. Significant history  of drug and/or food allergies  (as deemed  by [CONTACT_978]). 
13. Women of childbearing potential with a positive urine pregnancy test within [ADDRESS_196710]. 
14. Any contraindication to the use of nitroimidazoles,  or prior treatment  with pretomanid or 
delamanid.  
15. Treatment  with strong or moderate  CYP3A4  inducers or inhibitors2 within  14 days before 
admission and during the study3. 
2Except hormonal  contraceptives 
 
3In the opi[INVESTIGATOR_168690]: See Table  [ADDRESS_196711] of drugs  known to alter  the function  of CYP3A4  (Section  7.1.1 ). 
 
16. Use of St. John’s Wort within 7  days prior to  admission and during the entire  study. 
17. Consumption of products containing grapefruit within 5  days prior  to dosing until Visit 01N.  
18. Donation of whole blood or blood products >500 mL within 30 days from screening and/or 
plans to donate during the study or up to [ADDRESS_196712] study visit.  
20. Hgb <10.0 g/dL in both men and women  at the screening visit.  
DMID  Protocol  15-[ADDRESS_196713]  study 
result validity, or diminish the participant’s ability to undergo all study procedures and 
assessments.  
4In the opi[INVESTIGATOR_871] 
 
24. For men, semen donation for the duration of the study.  
25. AST  and ALT  > ULN.  
26. Bilirubin >  ULN  
 
Withdrawal  from  the Study or Study Termination  
 
Withdrawal from the  Study  
 
Participants may voluntarily withdraw their consent for trial participation at any time and for any 
reason, without penalty. 
A participant may withdraw  or be withdrawn from this trial for any of the following reasons:  
 
• Medical disease or condition, or any new clinical finding for which continued participation, in 
the opi[INVESTIGATOR_122740]- investigator, would compromise the safety of the 
participant,  or would interfere  with the participant's successful  completion  of this trial, or would 
interfere with the evaluation of data.  
• Participant  no longer meets  eligibility  criteria  (see Section  5.1). 
 
• As deemed necessary by [CONTACT_7880] [INVESTIGATOR_29353] -investigator for noncompliance or other 
reasons.  
• Withdrawal  of consent.  
 
• Lost to follow -up (defined as [ADDRESS_196714]  the participant; the methods and 
dates contact [CONTACT_168741]).  
• Termination  of this trial. 
 
A participant who is withdrawn or voluntarily withdraws from the study for any reason, whether related to the study drug or not, after having received the study drug, will be considered an early 
termination  subject. The PI [INVESTIGATOR_11637]- investigator will make every  effort to ensure that early  termination  

DMID  Protocol  15-[ADDRESS_196715] received  the study drug complete  the early  termination  assessments and safety 
follow -up assessments.  
 
Participant  Replacement  
 
Participants  who sign the informed  consent  form  (ICF)  and receive study product, and subsequently 
withdraw before the first [ADDRESS_196716] or rescreen and admit another time, if 
necessary.  
 
Study Termination  
 
If the study is prematurely terminated by [CONTACT_456], any regulatory authority, or the investigator for any reason, the investigator will promptly inform the study participants and assure appropriate 
therapy or follow -up for the participants, as necessary . The investigator will provide a detailed 
written explanation of the termination to the IRB/ Independent Ethics Committee (IEC).  

DMID  Protocol  15-0037  Version  11.0 
48  
 Renal Pharmacokinetics  11 April  2024  
 
6 STUDY  PROCEDURES  
 
Complete  study schedule details listed  by [CONTACT_168742]. Refer  also to 
APPENDIX A: Schedule of Study Procedures and Evaluations . 
 
Screening  
 
Visit 00A, Screening  Clinic  Visit  (Day  -28 to -7) 
 
• Participants  will be provided with a description  of this trial (purpose and study procedures) and 
asked  to read and sign the ICF. The ICF will be signed prior to performing  any study procedures.  
• Eligibility  criteria  will be  reviewed  with the participant.  
• Demographic variables (age, gender, race and ethnicity) and screening characteristics (height 
and weight) will be collected.  
• Complete  medical  history will be obtained by [CONTACT_168743].  
• All concomitant medications taken within 30 days prior to signing the ICF will be reported on the appropriate Data Collection Form (DCF).  
• Oral temperature,  sitting  blood pressure,  and sitting  pulse will be obtained. Participants  must not 
eat or drink anything hot or cold within 10 minutes prior to taking oral temperature.  
• A complete physical examination will be performed on all participants by a study clinician 
licensed  to make medical  diagnoses and listed  on the Form  FDA 1572 as the site PI [INVESTIGATOR_119251]-investigator.  
• A 12- lead ECG will be performed.  
• Height and weight will be obtained for  BMI  calculations.  
• Approximately 10 mL of venous blood will be collected for safety laboratory assessments including Hgb, BUN, serum creatinine (includes eGFR), ALT, AST, total bilirubin, serum potassium, and serum magnesium.  
• Approximately 12 mL of venous blood will be collected for HCV, hepatitis B surface antigen 
(HBsAg), and HIV testing.  
• Advise to refrain from alcohol use for at least 72  hours before admission.  
 
Visit 00B, 2
nd Screening  Clinic Visit (Day  -28 to -7) 
 
•
 Participant’s willingness  to participate  will be  reconfirmed and documented in the participant’s 
study source document records prior to performing any further study procedures.  

DMID  Protocol  15-0037  Version  11.0 
49  
 Renal Pharmacokinetics  11 April  2024  
 
• A urine pregnancy test will be performed on all women of childbearing potential and must be 
negative to ensure eligibility.  
• Urine  screen  for drugs.  
• Approximately 6 mL of venous blood will be collected  to screen  for alcohol or breath  collection 
if breathalyzer is used for alcohol testing  
• Remind  to refrain  from use of alcohol for 72 hours prior to hospi[INVESTIGATOR_063].  
 
Visit 00C, Hospi[INVESTIGATOR_91595],  Day -1 
 
• Participants  will be admitted  to the hospi[INVESTIGATOR_307] 12- [ADDRESS_196717].  
• Participant’s willingness  to participate  will be  reconfirmed and documented in the participant’s 
study source document records prior to performing any further study procedures.  
• Eligibility  criteria  will be reviewed  with the participant.  
• Interim medical history, including an assessment for new medical conditions and stability of 
chronic diseases, will be obtained by [CONTACT_168744] (Visit 00A) will be noted.  
• All concomitant medications will be reviewed with participants prior to the administration of 
study medication. Any new concomitant medications taken since the screening visit will be 
reviewed with participants and assessed for continued eligibility.  
• A urine pregnancy test will be performed on all women of childbearing potential and must be 
negative to ensure eligibility.  
• Urine  screen  for drugs.  
• Approximately 6 mL of venous blood will be collected  to screen  for alcohol or breath  collection 
if a breathalyzer is used for alcohol testing.  
• Alcohol and urine drug screening  will be performed, and results will be checked  when  available. 
Participants with positive results will be discharged unless the participants are on approved 
prescriptions.  However,  opi[INVESTIGATOR_168691],  which  are CYP3A4  substrates,  will not be 
allowed  even  if prescribed.  Participants  who are discharged  because of a positive  alcohol or urine 
drug screen will not be rescreened for enrollment.  
• If applicable, a peripheral intravenous catheter will be placed at this Visit or Visit 01A for 
participants with negative alcohol and drug screening except for participants who are on approved prescriptions. However, opi[INVESTIGATOR_168691], which are CYP3A4 substrates, will not be allowed even if prescribed.  
• Participants will be reminded that they must fast overnight (i.e., at least 8 hours). Participants 
will be required to bring in from home all their medications they take at home.  

DMID  Protocol  15-0037  Version  11.0 
50  
 Renal Pharmacokinetics  11 April  2024  
 
Dosing  (Day 1) and In-house  Confinement/  PK Collection  
 
Visit 01A, Administration  of Study Product  
 
• Eligibility  criteria  will be reviewed.  
• Interim medical history, including an assessment for new medical conditions and stability of 
chronic diseases,  will be obtained by [CONTACT_168745] (Visit 00C) will be noted.  
• Alcohol and urine drug screening results from Day -1 will be checked for participants whose 
alcohol and drug screening results were not available on time and who are not discharged on Day  
-1. Participants with positive results will be discharged unless the participants are on approved 
prescriptions. However, opi[INVESTIGATOR_168691], which are CYP3A4 substrates, will not be 
allowed even if prescribed. Participants who are discharged because of a positive alcohol or urine drug screen will not be rescreened for enrollment. 
• Vital signs, including oral temperature,  sitting  pulse,  and sitting  blood pressure,  will be obtained 
to ensure eligibility of participants with negative alcohol and urine drug screening results.  
• If applicable, a peripheral intravenous  catheter  will be placed  if not already  placed  on Visit 00C. 
• A targeted physical examination may be performed prior to administration of study product, if 
indicated  based  on review  of complete  medical  history and any updates obtained by [CONTACT_168746], by a study clinician licensed to make medical diagnoses 
and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator.  
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect  and measure urine volume for PK up to 1 hour pre-dose and again  after the dose has been 
administered; urine will be collected  in collection  beakers at [ADDRESS_196718] -dose. Urine volume will be  measured and 
recorded for each of these time intervals. Urine will be stored at room temperature and then 
frozen at - 20°C within 24 hours. Urine will be in ≤100 mL aliquots and stored at -20°C until 
shipped to Fisher Bioservices for storage. Fisher Bioservices will ship samples to bioanalytical 
laboratory for concentration measurements.  
• A urine pregnancy test will be performed prior to administration of the study product on all 
women of childbearing potential. Results must be negative and known prior to receipt of the study product.  
• Approximately [ADDRESS_196719] (up to 1 hour pre-dose).  
• Participants should start the recommended meal (high -fat and high- calorie, 
https:/ /www.fda.gov/media/121313/download)   30  minutes   prior   to  administration   of 

DMID  Protocol  15-0037  Version  11.0 
51  
 Renal Pharmacokinetics  11 April  2024  
pretomanid.  Study participants should eat this meal  in 30 ± 10 minutes  or less; however, 
pretomanid should be administered 30 ± 10 minutes after start of the meal.  
• Participants  will receive one dose of [ADDRESS_196720] 
supervision and a mouth check will be done. If a participant meets eligibility criteria and is 
admitted, but is not dosed, the participant may be re-evaluated for participation in the study.  
• Liquids, food, and medicine will not be allowed  until at least 2 hours after dosing.  
• All AEs/Serious Adverse Events (SAEs) will be recorded on the appropriate DCF/DMID SAE 
Report Form. 
 
Visit 01B, Day 1, Time 1 Hour ± [ADDRESS_196721] -dose; Hospi[INVESTIGATOR_7985] 
 
• A targeted physical examination may be performed if indicated based on new symptoms after 
administration of study product, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per 
Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be  collected  for PK.  
• All AEs/Serious Adverse Events (SAEs) will be recorded on the appropriate DCF/DMID SAE Report Form. 
 
Visit 01C, Day 1, Time  2 Hours  ± [ADDRESS_196722] -dose;  Hospi[INVESTIGATOR_7985]  
 
• A targeted physical examination may be performed if indicated based on new symptoms after 
administration of study product, by a study clinician licensed to make medical diagnoses and 
listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per 
Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be  collected  for PK.  
• All AEs/SAEs  will be recorded on the appropriate DCF/DMID SAE  Report  Form.  

DMID  Protocol  15-0037  Version  11.0 
52  
 Renal Pharmacokinetics  11 April  2024  
 
Visit 01D, Day 1, Time  4 Hours  ± [ADDRESS_196723] -dose;  Hospi[INVESTIGATOR_7985]  
 
• A targeted physical examination may be performed if indicated based on new symptoms after 
administration of study product, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be  collected  for PK.  
• All AE/SAEs  will be recorded on the appropriate DCF/DMID  SAE  Report Form.  
 
Visit 01E, Day 1, Time  5 Hour ± [ADDRESS_196724] -dose; Hospi[INVESTIGATOR_7985] 
 
• A targeted physical examination may be performed if indicated based on new symptoms after administration of study product, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per 
Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be  collected  for PK.  
• All AEs/SAEs  will be recorded on the appropriate DCF/DMID  SAE  Report  Form.  
 
Visit 01F, Day 1, Time 6 Hours ± [ADDRESS_196725] -dose;  Hospi[INVESTIGATOR_7985] 
 
• A targeted physical examination may be performed if indicated based on new symptoms after 
administration of study product, by a study clinician licensed to make medical diagnoses and 
listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per 
Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be  collected  for PK.  
• All AEs/SAEs  will be recorded on the appropriate DCF/DMID  SAE  Report  Form.  

DMID  Protocol  15-0037  Version  11.0 
53  
 Renal Pharmacokinetics  11 April  2024  
 
Visit 01G, Day 1, Time 8 Hour ± [ADDRESS_196726]-dose; Hospi[INVESTIGATOR_7985] 
 
• A targeted physical examination may be performed if indicated based on new symptoms after 
administration of study product, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be  collected  for PK.  
• All AE/SAEs  will be  recorded  on the appropriate DCF/DMID  SAE  Report Form.  
 
Visit 01H, Day 1, Time  12 Hours ± [ADDRESS_196727] -dose;  Hospi[INVESTIGATOR_7985] 
 
• Vital signs, including oral temperature,  sitting  blood  pressure,  and sitting  pulse  will be obtained. 
Participants must not eat or drink anything hot or cold within 10 minutes prior to taking oral temperature.  
• A targeted physical examination may be performed if indicated based on new symptoms after 
administration of study product, by a study clinician licensed to make medical diagnoses and 
listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per 
Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be collected  for PK.  
• All AEs/SAEs  will be recorded on the appropriate DCF/DMID  SAE  Report  Form.  
 
Visit 01I, Day 1, Time  16 Hour ± [ADDRESS_196728]-dose;  Hospi[INVESTIGATOR_7985]  
 
• A targeted physical examination may be performed if indicated based on new symptoms after 
administration of study product, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637] -investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per 
Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be collected  for PK.  
• All AE/SAEs  will be recorded on the appropriate DCF/DMID  SAE  Report Form.  

DMID  Protocol  15-0037  Version  11.0 
54  
 Renal Pharmacokinetics  11 April  2024  
 
Visit 01J, Day 2, Time 24 Hour ± [ADDRESS_196729]-dose; Hospi[INVESTIGATOR_7985]  
 
• Vital signs, including oral temperature,  sitting  blood  pressure,  and sitting  pulse  will be obtained. 
Participants must not eat or drink anything hot or cold within 10 minutes prior to taking oral 
temperature.  
• A targeted physical examination may be performed if indicated based on new symptoms after administration of study product, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be  collected  for PK.  
• All AEs/SAEs  will be recorded on the appropriate DCF/DMID SAE  Report  Form.  
 
Visit 01K, Day 2, Time 36 Hour ± [ADDRESS_196730]-dose;  Hospi[INVESTIGATOR_7985] 
 
• A targeted physical examination may be performed if indicated based on new symptoms after administration of study product, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per 
Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be  collected  for PK.  
• All AEs/SAEs  will be recorded on the appropriate DCF/DMID SAE  Report  Form.  
 
Visit 01L, Day 3, Time 48 Hours ± [ADDRESS_196731]-dose, Hospi[INVESTIGATOR_7985] 
 
• A targeted physical examination may be performed if indicated based on new symptoms after 
administration of study product, by a study clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637]-investigator. 
• All concomitant medications will be recorded  on the appropriate DCF.  
• Vital signs, including oral temperature,  sitting  blood  pressure,  and sitting  pulse  will be obtained. 
Participants must not eat or drink anything hot or cold within 10 minutes prior to taking oral 
temperature.  
• Collect all urine for PK, measure and record urine PK volume, aliquot, label and freeze per 
Section [IP_ADDRESS]. 

DMID  Protocol  15-0037  Version  11.0 
55  
 Renal Pharmacokinetics  11 April  2024  
 
• Approximately 4 mL of venous blood will be  collected  for PK.  
• If applicable, the intravenous catheter will be  removed by a nurse or physician.  
• Provide urine PK collection instructions and containers. Instruct the participant to collect urine 
for 2 more days at home and keep urine container at room temperature with the cap on.  
• Discharge after  review  by [CONTACT_168747] 1572 as the site PI [INVESTIGATOR_11637]- investigator. Note: Participants may remain in the hospi[INVESTIGATOR_168692].  
• All AEs/SAEs  will be recorded on the appropriate DCF/DMID SAE  Report  Form.  
 
Follow -Up 
 
Visit 01M, Day 4, Time 72 Hours ± [ADDRESS_196732] -dose, Clinic Visit or Continued  
Hospi[INVESTIGATOR_7985], per Site Decision  
• Interim medical history, including an assessment for new medical conditions and stability of 
chronic diseases,  will be obtained by [CONTACT_168748].  
• A targeted physical examination may be performed if indicated based on review of interim 
medical  history, by a study  clinician  licensed  to make medical  diagnoses and listed  on the Form 
FDA 1572 as the site PI [INVESTIGATOR_11637]- investigator.  
• All concomitant medications will be recorded  on the appropriate DCF.  
• Vital signs, including oral temperature,  sitting  blood  pressure,  and sitting  pulse  will be obtained. 
Participants must not eat or drink anything hot or cold within 10 minutes prior to taking oral 
temperature.  
• Receive home urine collected jug from subject. Measure and record urine PK volume, aliquot, 
label and freeze per Section [IP_ADDRESS]. 
• Provide urine PK collection container and remind the participant to collect urine at home and 
keep urine container at room temperature with cap on for PK. 
• Approximately 4 mL of venous blood will be collected  for PK.  
• All AE/SAEs  will be recorded  on the appropriate DCF/DMID  SAE  Report Form.  

DMID  Protocol  15-0037  Version  11.0 
56  
 Renal Pharmacokinetics  11 April  2024  
 
Visit 01N, Day 5, Time 96 Hours  ± [ADDRESS_196733]-dose, Clinic Visit  or Continued 
Hospi[INVESTIGATOR_7985], per Site Decision  
• Interim medical history, including an assessment for new medical conditions and stability of 
chronic diseases,  will be obtained by [CONTACT_168748].  
• A targeted physical examination may be performed if indicated based on review of interim 
medical  history, by a study  clinician  licensed  to make medical  diagnoses and listed  on the Form 
FDA 1572 as the site PI [INVESTIGATOR_11637]- investigator.  
• All concomitant medications will be recorded  on the appropriate DCF.  
• Vital signs, including oral temperature,  sitting  blood  pressure,  and sitting  pulse  will be obtained. 
Participants must not eat or drink anything hot or cold within 10 minutes prior to taking oral temperature.  
• A 12- Lead  ECG will be  performed.  
• Receive home urine collected jug from subject. Measure and record urine PK volume, aliquot, 
label and freeze per Section [IP_ADDRESS]. 
• Approximately 4 mL of venous blood will be collected  for PK.  
• All AE/SAEs  will be recorded  on the appropriate DCF/DMID  SAE  Report Form.  
• Approximately 10 mL of venous blood will be collected for safety laboratory assessments 
including Hgb, BUN, serum creatinine (includes eGFR), ALT, AST, total bilirubin, serum 
potassium, and serum magnesium.  
• If hospi[INVESTIGATOR_168693], discharge after review by [CONTACT_168749] 1572 as the site PI [INVESTIGATOR_11637]-investigator.  
 
 
Visit 02, Day 12 ± [ADDRESS_196734]-dose, Clinic Visit  
 
• Interim medical history, including an assessment for new medical conditions and stability of 
chronic diseases,  will be obtained by [CONTACT_168748].  
• A targeted physical examination may be performed on all participants by a study clinician 
licensed  to make medical  diagnoses and listed  on the Form  FDA 1572 as the site PI [INVESTIGATOR_119251]-investigator.  
• All concomitant medications will be recorded  on the appropriate DCF.  

DMID  Protocol  15-0037  Version  11.0 
57  
 Renal Pharmacokinetics  11 April  2024  
 
• Vital signs, including oral temperature,  sitting  blood  pressure,  and sitting  pulse  will be obtained. 
Participants must not eat or drink anything hot or cold within 10 minutes prior to taking oral 
temperature.  
• A urine pregnancy test will be performed  on all women  of childbearing potential.  
• All AE/SAEs  will be recorded on the appropriate DCF/DMID  SAE  Report Form.  
• Approximately 10 mL of venous blood will be collected for safety laboratory assessments 
including Hgb, BUN, serum creatinine (includes eGFR), ALT, AST, total bilirubin, serum potassium, and serum magnesium.  
 
Final  Visit,  Visit  03, Day 85+[ADDRESS_196735]-dose,  Phone  Visit  
• The participant will be asked  if they or their partner became pregnant. If  the participant became 
pregnant, the Pregnancy Report and Follow -Up forms will be completed. If the participant’s 
partner became pregnant, details about the pregnancy should be reported to the sponsor to document the outcome of the pregnancy. All SAEs will be recorded on the appropriate DCF/DMID SAE Report Form.  
 
Early  Termination Visit  (if needed)  
 
The following activities will be performed at the early termination (ET) visit on participants who  
withdraw, or are withdrawn or terminated from this trial:  
• Obtain  interim  medical history,  including an assessment  of new symptoms and conditions from 
the patient, and note any changes since the previous visit.  
• A targeted review of systems. For participants with renal impairment, this targeted review of systems will also focus on renal disease and will include questions pertaining to changes in the frequency and volume of urine, requirement for dialysis, and mental status.  
• Targeted  physical examination, if needed.  
• All concomitant medications will be recorded  on the appropriate DCF.  
• Assess for AEs/SAEs.  
• Urine  pregnancy test for females  of childbearing potential.  
• Vital signs including oral temperature,  sitting  blood pressure,  and sitting  pulse  will be obtained.  
• Approximately 10 mL of venous blood will be collected for safety laboratory assessments 
including Hgb, BUN, serum creatinine (includes eGFR), ALT, AST, total bilirubin, serum 
potassium, and serum magnesium.  

DMID  Protocol  15-0037  Version  11.0 
58  
 Renal Pharmacokinetics  11 April  2024  
 
Unscheduled Visit  (if needed)  
Unscheduled visits will be allowed  for the following reasons:  
• Management  of AEs  and SAEs.  
• Performance  of repeat or additional laboratory tests for clinically  abnormal test values.  
• For a repeat urine  pregnancy test if the participant  suspects pregnancy.  
• Anytime  the investigator  believes that it is clinically  appropriate for patient safety.  
 
Protocol  Deviations 
 
A protocol deviation is any noncompliance with the clinical  trial protocol, or protocol- specific MOP 
requirements.  The noncompliance may be either  on the part of the participant, the site PI, or the site 
personnel. As a result of deviations, corrective actions are to be developed by [CONTACT_90478].  
It is the responsibility  of the site PI [INVESTIGATOR_168694] [ADDRESS_196736] be promptly  reported  to DMID 
per the Statistical Data Coordinating Center (SDCC) protocol deviation reporting procedures. 
All deviations, as defined above, must be addressed in study participant DCFs. A completed copy 
of the DMID Protocol Deviation Form must be maintained in the regulatory file, as well as the 
participant’s chart. Protocol deviations must be sent to the local IRB/IEC per their guidelines. The site PI [INVESTIGATOR_168695].  

DMID  Protocol  15-[ADDRESS_196737], liver, pancreas, 
kidneys, urologic system, nervous system, blood,  lymph nodes, endocrine system, musculoskeletal 
system, skin, and genital/reproductive tract. A history of any allergies, cancer, immunodeficiency, psychiatric illness, substance abuse, and autoimmune disease will be solicited.  
During the hospi[INVESTIGATOR_4408], any new symptoms after study product administration will be collected. 
After hospi[INVESTIGATOR_2345], an interim medical history will be obtained by [CONTACT_168750]. 
Medications history  (concomitant medications) will include a review  of all  current  medications and 
medications as specified in Section 7.1.1. Assessment of eligibility will include a review of all 
permitted and prohibited medications per the participant inclusion and exclusion criteria (see 
Sections 5.1.1 and 5.1.2). In addition, the site PI  [INVESTIGATOR_29353]- investigator may identify other 
medications that should not be used due to a risk to participant safety or possible effects on PK parameters.  
At the first visit (Visit 00A)  a physical examination  will be performed  on all participants  to include 
the following  organs and organ systems:  skin, head, eyes,  ears, nose and throat, thyroid, neurological 
system, chest and lungs, cardiovascular system, abdomen, lymph nodes, musculoskeletal system, and extremities by a study clinician licensed to make medical diagnoses and listed on the Form FDA  
[ADDRESS_196738], a targeted physical examination may be performed, if indicated based on the participant’s interim medical history, by a study c linician licensed to make medical 
diagnoses and listed on the Form FDA [ADDRESS_196739] include  the participant’s  sitting  pulse, sitting  blood pressure (mm  Hg), 
and oral body temperature (ºF) at the screening Visit 00A, 01A, 12, 24, 48, 72, and [ADDRESS_196740] administration.  Height and weight will  be obtained at screening 
Visit 00A only. If a physiologic parameter,  e.g., vital signs,  is outside of the protocol- specified  range 
(for control participants)  or outside the patient’s  baseline (for renally  impaired  participants),  then the 
measurement  may be repeated  once if, in the judgment of the investigator,  the abnormality  is the 

DMID  Protocol  15-0037  Version  11.0 
60  
 Renal Pharmacokinetics  11 April  2024  
result of an acute, short -term, rapi[INVESTIGATOR_168696] (e.g., stress, anxiety, or “white coat 
syndrome”). The participant’s baseline is the latest vital sign recorded in their electronic health 
record (EHR) in the last 3 months before screening. For participants with CKD but no vital signs 
recorded  in their  EHR,  the protocol- specified  range  used  for control participants  will be used. Once 
participants are dosed, the vital signs measured at Visit 01A will be considered their baseline. A 
physiologic parameter may also be repeated if there is a technical problem with the measurement 
caused by a malfunction, or an inappropriate measuring device (i.e., inappropriate -sized blood 
pressure cuff).  If there  is an abnormal blood pressure measurement,  the participant should lay down 
for 10 minutes and then the measurement should be repeated while the participant is awake and 
resting  supi[INVESTIGATOR_050]. For  analyzing secondary  safety  endpoints in rescreened  participants  (if any) and that 
include a comparison to screening baseline values should have the rescreening values as baseline.  
In addition, a 12- lead ECG will be performed  at Screening  Visit 00A and Visit 01N. If at Visit  01N 
the ECG is abnormal, it can be repeated. 
At subsequent visits,  assessment  for AEs and SAEs  will occur and the participant will be interviewed 
about interim AEs/SAEs and medical history.  
Participants will be admitted for multiple blood draws following oral administration of study 
product. Any AEs/SAEs  will be recorded  on the appropriate DCF/DMID  SAE  Report Form  prior to 
discharge from the hospi[INVESTIGATOR_307].  
 
Assessment  of Concomitant Medications/Treatments Other  Than  Study  Product  
 
Administration  of any medications, therapi[INVESTIGATOR_014],  or vaccines will  be recorded on the appropriate DCF. 
Concomitant medications  will include all current medications  and medications taken  in the 30 days 
prior to signing the ICF through approximately 11 days after the study medication is given, ET or unscheduled visits (if prior to [ADDRESS_196741] administration), whichever occurs first. Medications reported are limited  to those  taken  within  30 days prior to the study medication  through 
approximately 11 days after the study medication. Prescription and over -the- counter drugs will be 
included as well as vitamins, and supplements (including herbal). 

DMID  Protocol  15-0037  Version  11.0 
61  
 Renal Pharmacokinetics  11 April  2024  
Table 4: Prohibited Strong  and Moderate CYP450  Enzyme  Inducer  or Inhibitor 
Medications/Substances per Participant Exclusion Criteria  
CYP3A  (including  3A4)  inhibitors  and inducers  
Strong  inhibitors  Moderate  inhibitors  Strong  inducers  Moderate  inducers  
• Adagrasib  
• Atazanavir  
• Ceritinib  
• Clarithromycin  
• Cobicistat and 
cobicistat -containing 
coformulations  
• Darunavir  
• Idelalisib  
• Indinavir  
• Itraconazole  
• Ketoconazole  
• Levoketoconazole 
• Lonafarnib  
• Lopi[INVESTIGATOR_054]  
• Mifepristoned 
• Nefazodone  
• Nelfinavir  
• Nirmatrelvir -ritonavir  
• Ombitasvir - 
paritaprevir- ritonavir  
• Ombitasvir - 
paritaprevir- ritonavir 
plus dasabuvir  
• Posaconazole  
• Ritonavir and 
ritonavir -containing 
coformulations  
• Saquinavir  
• Tucatinib  
• Voriconazole  • Amiodaronea 
• Aprepi[INVESTIGATOR_053]  
• Berotralstat  
• Cimetidinea 
• Conivaptan  
• Crizotinib  
• Cyclosporinea 
• Diltiazem  
• Duvelisib  
• Dronedarone 
• Erythromycin  
• Fedratinib  
• Fluconazole  
• Fosamprenavir  
• Fosaprepi[INVESTIGATOR_168697] 
• Fosnetupi[INVESTIGATOR_053] - 
palonosetron  
• Grapefruit  juice  
• Imatinib  
• Isavuconazole 
(isavuconazonium 
sulfate)  
• Lefamulin  
• Letermovir  
• Netupi[INVESTIGATOR_053]  
• Nilotinib  
• Ribociclib  
• Schisandra  
• Verapamil  • Apalutamide  
• Carbamazepi[INVESTIGATOR_050] 
• Enzalutamide  
• Fosphenytoin  
• Lumacaftor  
• Lumacaftor - 
ivacaftor  
• Mitotane  
• Phenobarbital  
• Phenytoin  
• Primidone  
• Rifampin 
(rifampi[INVESTIGATOR_2513])  • Bexarotene  
• Bosentan  
• Cenobamate  
• Dabrafenib  
• Dexamethasoneb 
• Dipyrone 
• Efavirenz  
• Elagolix, estradiol, 
and norethindrone therapy pack
c 
• Eslicarbazepi[INVESTIGATOR_050]  
• Etravirine  
• Lorlatinib  
• Mitapi[INVESTIGATOR_168698]  
• Modafinil  
• Nafcillin  
• Pexidartinib  
• Rifabutin  
• Rifapentine  
• Sotorasib  
• St. John's  wort 
CYP=cytochrome  P450;  FDA=Food  and Drug  Administration;  US=United  States  (of America) 
From https ://www.uptodate.com/contents/image?imageKey=CARD%2F76992  
For drug interaction  purposes,  inhibitors  and inducers  of CYP3A  metabolism  listed  above  can alter serum  concentrations 
of drugs that are dependent upon the CYP3A subfamily of liver enzymes, including CYP3A4, for elimination or 
activation.  
These classifications  are based  upon  US FDA  guidance  [41, 42]. Other  sources  may use a different  classification  system 
resulting in some agents being classified differently.  
Data are for systemic drug forms. Degree of inhibition or induction may be altered by [CONTACT_2715], method, and timing of 
administration.  
Weak inhibitors and inducers are not listed in this table with exception of a few examples. Clinically significant 
interactions  can occasionally  occur  due to weak  inhibitors  and inducers  (e.g., target  drug is highly  dependent  on CYP3A4 
metabolism and has a narrow therapeutic index). Accordingly, specific interactions should be checked using a drug interaction program such as the Lexicomp drug interactions program included within UpToDate.  
DMID  Protocol  15-0037  Version  11.0 
62  
 Renal Pharmacokinetics  11 April  2024  
 
Refer  to UpToDate  topi[INVESTIGATOR_168699].  
a Classified  as a weak  inhibitor  of CYP3A4  according  to FDA  system [41]. 
b Classified  as a weak  inducer  of CYP3A4  according  to FDA system [41]. 
c  The fixed -dose combination therapy  pack taken in the  approved regimen has moderate CYP3A4 induction  effects. 
When  Elagolix  is used as a single  agent,  it is a weak  CYP3A4  inducer.  Norethindrone  and estradiol  are not CYP3A4 
inducers.  
d  Mifepristone is a significant inhibitor of CYP3A4 when used chronically (e.g., for hyperglycemia in patients with 
Cushing syndrome); not in single -dose use.  
 
Laboratory Evaluations 
 
Clinical Laboratory Evaluations  
 
Clinical laboratory  parameters to be evaluated  prior to the study  product administration  on screening 
visit (Visit 00A),  on Day  5 (Visit 01N)  and on Day 12 (Visit 02) will include Hgb, ALT,  AST,  total 
bilirubin, BUN, serum creatinine (includes eGFR), serum potassium and serum magnesium . HIV, 
HBsAg, and HCV will be obtained at Visit 00A only. Screening laboratory assessments may be 
repeated once per investigator discretion.  
Urine pregnancy tests will be performed locally on all women of childbearing potential by [CONTACT_168751] (Visit 00B), on the day of hospi[INVESTIGATOR_063] (Visit 00C), prior to 
administration  of study product (Visit  01A), at Visit 02, and ET. Results must  be negative and known 
prior to administration of study product. Urine drug screen and alcohol screen will also be done on 
Visit 00B and 00C. 
 
Research  Assays  
 
All PK samples collected in the study will be analyzed using validated bioanalytical methods for 
pretomanid, and the metabolites, M19 and M50 in plasma and urine. 
Blood samples will  be collected (dipotassium ethylenediaminetetraacetic  acid [K2 EDTA] tubes)  in 
this study to  characterize the PK  of pretomanid in  non- renally  impaired  controls  and in  participants 
with renal  impairment (see PK sampling  points in APPENDIX  A: Schedule of Study Procedures and 
E
valuations . 
The exact date and time of collection of all PK blood and urine samples will be recorded. The pre - 
dose blood sample  will be collected  up to [ADDRESS_196742] be ± [ADDRESS_196743]  be within  
± [ADDRESS_196744] be within ±  4 
hours from the nominal time.  
Dates should be recorded in an unambiguous format (e.g., DDMMMYYYY), and time should be 
recorded  to the nearest  minute (e.g., HH:MM  using the 24-hour clock). Blood samples drawn  outside  

DMID  Protocol  15-0037  Version  11.0 
63  
 Renal Pharmacokinetics  11 April  2024  
of the defined window should not be considered protocol deviations. Blood samples that are not 
drawn should be recorded and reported as protocol deviations. 
[IP_ADDRESS] Laboratory Specimen  Preparation,  Handling,  and Shippi[INVESTIGATOR_168700], handling, and storage are included in the central (clinical) 
laboratory manual and protocol -specific MOP as appropriate.  
Briefly,  whole blood will be collected  into commercially  available anticoagulant (K2 EDTA) -treated 
tubes. Cells including platelets will be removed from plasma by [CONTACT_7873] 15 minutes at 2,000 x g using a refrigerated  centrifuge. The resulting  supernatant  is designated plasma.  Following 
centrifugation, the plasma  will be  transferred into a  clean polypropylene  tube using sterile pi[INVESTIGATOR_6343]. 
The plasma samples will be apportioned into 0.5 mL aliquots immediately while the samples are maintained at 2 –8°C. The aliquots will be stored at –20°C or colder. 
The urine PK of a single dose of pretomanid will be assessed from urine collected at up to [ADDRESS_196745] -dose. Urine volume will be 
measured and recorded for each of these time intervals. Urine w ill be stored at room temperature 
and then frozen at - 20°C within 24 hours. Urine will be in ≤100 mL aliquots and stored at -20°C 
until shipped to Fisher Bioservices.  The rest of  the urine will be  stored  until the  study is completed.  
[IP_ADDRESS] Laboratory Specimen  Shipment  
 
Specimen shipment will occur at intervals during the course of this trial following all applicable 
International Air Transport Association (IATA) requirements and according to the specifics for storage temperature and documentation as detailed in the proto col-specific MOP as appropriate.  
Plasma and urine PK samples will be shipped on dry ice to Fisher Bioservices prior to sending to 
the bioanalytical laboratory measuring concentrations of pretomanid and its metabolites (M19 and 
M50).  
Instructions  for specimen  shipment are  included in the protocol- specific MOP, as appropriate.  
DMID  Protocol  15-0037  Version  11.0 
64  
 Renal Pharmacokinetics  11 April  2024  
 
8 ASSESSMENT  OF SAFETY  
 
Assessing  and Recording  Safety Parameters  
 
Safety  will be assessed  by [CONTACT_168752]:  
 
1. SAEs ( Section 8.1.2) occurring from the time of the study product administration through  Visit 
03, Day 85+[ADDRESS_196746] administration (Visit 01A) 
through Visit 02, Day 12 ± [ADDRESS_196747] administration 
(Visit 01A) through Visit 02 Day 12 ± [ADDRESS_196748], ALT, total bilirubin, BUN, serum creatinine, eGFR, and serum potassium and magnesium. 
All AEs/SAEs will be  followed until resolution.  
 
Adverse Events  
 
Adverse Event  (AE):  The International Council for Harmonisation  (ICH)  E6 defines an AE as any 
untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical  product regardless of its causal  relationship  to the study treatment.  The FDA defines 
an AE as any untoward medical  occurrence associated  with the use of a drug in humans, whether or 
not considered drug related. 
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal (investigational) 
product. The occurrence of  an AE  may come  to the  attention of study personnel during study visits 
and interviews  of a study  participants  presenting for medical  care, or upon  review  by a study monitor.  
All AEs,  systemic (participative  and quantitative) reactions from  Day  1 to the end of  the study, will 
be captured on the appropriate (source documentation and eCRF) ( Section 8.3). Information to be 
collected for AEs includes event description, date of onset, assessment of severity, relationship to 
study product and alternate etiology (assessed  only by [CONTACT_168753] 
a diagnosis and listed  on the Form  FDA 1572 as an investigator),  date of resolution, seriousness,  and 
outcome. AEs occurring during the trial collection and reporting period will be documented 
appropriately regardless  of relationship to  the study product. AEs  will be followed  through resolution 
or until stable. 
Any medical condition(s) that is/are present at the time that the participant is screened will be 
co
nsidered  as baseline and not reported  as an AE but must be reported  in the medical  history  

DMID  Protocol  15-0037  Version  11.0 
65  
 Renal Pharmacokinetics  11 April  2024  
(APPENDIX A: Schedule of Study Procedures and Evaluations ). However, if the severity of any 
pre-existing medical condition increases, it will be recorded as an AE ( Section 8.3 ). 
[IP_ADDRESS] Adverse Events  Grading  
 
All AEs, including laboratory and clinical symptoms, will be graded for severity according to the 
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, November 2017 
(https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50), and 
assessed  for relationship  to study product. AEs characterized  as intermittent require  documentation 
of onset and duration of each epi[INVESTIGATOR_1865].  The start and stop date of each reported  AE will be recorded 
on the appropriate DCF and eCRF. 
Severity  of Event:  
• Mild (Grade 1): Asymptomatic or mild symptoms, Events require minimal or no treatment and 
do not interfere with the participant’s daily activities.  
• Moderate (Grade 2) : Events result in a low level of inconvenience or concern with therapeutic 
measures. Moderate events may cause some interference with functioning and daily activities.  
• Severe (Grade  3): Severe or medically  significant  but not immediately  life threatening, interrupt 
the participant’s  daily  activities; and may require intervention and hospi[INVESTIGATOR_059]. Severe events 
are usually incapacitating.  
• Life-threatening  (Grade  4): Life-threatening consequences; urgent intervention  indicated.  
AEs characterized  as intermittent require documentation of onset  and duration of each epi[INVESTIGATOR_1865].  
 
Relationship to Study Product: The assessment of the AE’s relationship to study product will be 
performed by a delegated, licensed study clinician listed on the Form FDA 1572. The assessment 
will be part of the documentation process. Whether the AE is related or not is not a factor in 
determining what is or is not reported in this trial. If there is any doubt as to whether a clinical 
observation is an AE, the event  should be reported. In  a clinical  trial, the study product must always 
be suspect. To help assess the relationship, the following guidelines will be used: 
• Related  – There is a reasonable possibility that the study product caused the AE. Reasonable 
possibility means that there is evidence to suggest a causal relationship between the study 
product and the AE. 
• Not Related  – There is not a reasonable possibility that the administration of the study product 
caused the event.  
 
Serious  Adverse Events  
 
Serious Adverse Event (SAE): An AE or suspected adverse reaction is considered “serious” if, in 
the view of either the site PI [INVESTIGATOR_10157], it results in any of the following outcomes:  

DMID  Protocol  15-0037  Version  11.0 
66  
 Renal Pharmacokinetics  11 April  2024  
 
• Death,  
• A life-threatening AE*,  
• Inpatient hospi[INVESTIGATOR_707],  
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or 
• A congenital anomaly/birth  defect.  
*An AE is considered  “life-threatening”  if, in the view of either the site PI [INVESTIGATOR_10157], its occurrence 
places the patient or participant at immediate risk of death. It does not include an AE that, had it 
occurred in a more severe form, might have caused death.  
Important medical  events that may not result  in death,  be life-threatening, or require hospi[INVESTIGATOR_168701], based  upon appropriate medical  judgment they may jeopardize the 
health or safety of the patient or participant and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not  result in  inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse. 
SAEs  will be:  
 
• Assessed for severity and relationship to study product and alternate etiology (if not related to 
study product). 
• Recorded  on the appropriate DCF and eCRF, and on the DMID  SAE Report  Form.  
• Followed through resolution.  
• Reviewed and evaluated by [CONTACT_114798], SMC (periodic review unless related), and the IRB per 
reporting requirements. 
At any time after the protocol follow -up period or completion of this study, if the site PI [INVESTIGATOR_168702]- investigator becomes aware of an SAE that is suspected to be related to study 
product, the site PI [INVESTIGATOR_29353]- investigator will report th e event to the DMID 
Pharmacovigilance Group. 
 
Specification of Safety Parameters  
 
There  are no solicited events to be  captured for this study.  

DMID  Protocol  15-[ADDRESS_196749]  be submitted  immediately  (within 
24 hours of site awareness) on a PDF -fillable SAE form to the DMID Pharmacovigilance 
Group at the following address: 
DMID  Pharmacovigilance Group  
Clinical Research  Operations  and Management Support  (CROMS) 
[ADDRESS_196750]. Suite 650 
Bethesda,  MD [ZIP_CODE], US 
SAE Hot Line:  1-800- 537-9979 (US)  or [PHONE_2619] (outside  US) 
SAE FAX: 1 -[PHONE_1729] (US) or [PHONE_2621] (outside US) 
SAE Email Address:  [EMAIL_1393]  
 
In addition to the SAE form, selected SAE data fields must also be entered into the SDCC system (for example Advantage eClinical). Please see the protocol -specific MOP for details regarding this 
procedure.  
Other supporting documentation of the event may be requested by [CONTACT_154385]. 
The site will send a copy of the SAE report(s) to the DMID Pharmacovigilance Group. The DMID 
Medical Monitor and DMID Clinical Project Manager will be notified of the SAE by [CONTACT_168754]. The DMID Medical Monitor will review and assess the SAE for 
regulatory reporting and potential impact on study participant safety and protocol conduct. 

DMID  Protocol  15-[ADDRESS_196751] and the 
AE. DMID will notify the FDA and all participating  site investigators  (i.e., all investigators  to whom 
the sponsor is providing drug under its  IND[s]  or under any PI’s IND[s]) in  an IND safety  report  of 
potential serious risks  from  clinical trials  or any other source,  as soon as possible, but in no case later 
than 15 calendar days after the sponsor determines that the information qualifies for reporting as 
specified in US 21 CFR Part 312.32. DMID will also notify the FDA of any unexpected fatal or life -
threatening suspected adverse reaction as soon as possible, but in no case later than 7 calendar days after the sponsor’s initial  receipt  of the information.  Relevant  follow-up information  to an IND safety  
report will be submitted  as soon as the information  is available.  Upon request  from the  FDA, DMID 
will submit to FDA any additional data or information that the agency deems necessary, as soon as 
possible, but in no case later than [ADDRESS_196752].  
All serious events designated as “not related” to study product(s), will be reported to FDA at least annually in a summary format.  
 
Reporting  of Pregnancy  
 
Pregnancies occurring in female  study participants  will be reported  via Advantage eClinical
® on the 
Pregnancy Report form. With the participant’s permission all protocol- required venous blood 
samples will be obtained and the participant  will continue to  be followed for safety  for the duration 
of this  trial.  Efforts  will be  made to  follow  all pregnancies reported during  the course of this trial to 
pregnancy outcome pending the participant’s permission. 
Male pa rticipants will be asked  if their female  partner  has become  pregnant during the study and any 
pregnancy will be reported. The outcome of pregnancy in the female  partner of male  participant will 
be handled through contact [CONTACT_168755]. 
 
Type  and Duration of Follow -up of Participants After  Adverse Events  
 
AEs/SAEs  will be collected,  assessed,  and followed through resolution  from  the time of study 
product administration through approximately [ADDRESS_196753]. 

DMID  Protocol  15-0037  Version  11.0 
69  
 Renal Pharmacokinetics  11 April  2024  
Resolution of an AE/SAE  is defined  as the return  to pretreatment  status  or stabilization  of the 
condition with the expectation that it will remain chronic.  
Follow-up procedures, evaluations, and outcomes will be recorded  on the appropriate DCF.  
 
Procedures to be Followed in the Event of Abnormal Laboratory Test 
Values or Abnormal Clinical Findings  
The site PI [INVESTIGATOR_29353]- investigator is responsible for recording all AE/SAEs  that are observed 
or reported during this trial, regardless of the relationship to study product. AE/SAEs, abnormal 
laboratory test values, or abnormal clinical findings will be collected, assessed, documented, 
reported, and followed appropriately, using a local la boratory as necessary. Participants with 
elevated aminotransferase and/or bilirubin will be asked about recent seizures and mental health status change. In determining eligibili ty, refer to Section 5.1 and the protocol- specific MOP.  
Clinical and safety  laboratory results  will be graded  for severity  according to the CTCAE 
Version 5.0, November 2017 (see Section [IP_ADDRESS] ). 
 
Halting Rules 
 
Study  Halting  Criteria  
 
The study will be immediately suspended, and no additional doses administered if any of the following occurs: 
• Any death  occurring during the study that was not the result  of trauma  or accident.  
• Two or more  participants experience  an SAE,  related  to the study product.  
• Three  or more  participants  in each part of the trial (A or B)  develop a severe,  Grade  3 or higher, 
AE, systemic or laboratory, in the same MedDRA Low Level Term (LLT), assessed as related 
to the study product. 
If any halting  criterion  is met, the study  will be suspended, and a SMC  ad hoc meeting  will convene. 
The study will not be re-started  until the SMC  meets  and provides its recommendation  to DMID,  the 
study sponsor. 

DMID  Protocol  15-0037  Version  11.0 
70  
 Renal Pharmacokinetics  11 April  2024  
 
Safety Oversight  
 
Safety  Monitoring  Committee  (SMC)  
 
This study will utilize a SMC, which is an independent group of experts that advises DMID. The 
primary responsibility of the SMC is to monitor participant safety. The SMC is external to DMID 
and is composed of at least [ADDRESS_196754]-free basis independently of the 
study team.  The DMID or the SMC  may convene ad hoc meetings  of the SMC  according  to protocol 
criteria or if there are concerns that arise during the study.  
The SMC will review  the safety  data at the following milestones:  
• Organizational meeting (prior to start of the study).  
• After 6 participants in Group 2 (severe renal impairment and ESRD, not on dialysis) and their 
matching controls are enrolled and complete follow -up through Day 12 (Visit 02). This review 
will be completed prior to determining if Part B will be conducted and opening enrollment for 
Groups 3 and 4 and their matched healthy control participants. 
• An ad hoc SMC meeting will be convened when a halting rule is met, or at the request of the 
investigator and/or DMID if there are safety concerns during the course of the study. 
• Final Data Review Meeting: Approximately [ADDRESS_196755] 
summary  format.  The SMC  may  be asked  to provide  recommendations in response to  questions 
posed by [CONTACT_122830]. 
• The DMID Medical  Monitor is empowered  to stop study enrollment if AEs that meet  the halting 
criteria  are reported or if  any serious safety concerns  arise.  The DMID Medical  Monitor will be 
responsible for reviewing  SAEs  in real time.  The SMC  will review  SAEs  on a regular  basis and 
ad hoc during the study. 

DMID  Protocol  15-[ADDRESS_196756]  
 
The site PI [INVESTIGATOR_168703]/her research  site(s) and 
send supporting documentation to the DMID before initiating recruitment of participants. The 
investigator will submit applicable information to the IRB on which it relies for the review, to conduct the review in accordance with 45 CFR 46, ICH E6 Good Clinical Practice (GCP), and as 
applicable, 21 CFR  56 (IRB)  and 21 CFR 50 (Protection  of Human  Participants),  other federal,  state, 
and local regulations. The IRB must be registered with the Office for Human Research Protections 
(OHRP) as applicable to the research. DMID must receive the documentation that verifies IRB 
approval  for this protocol, associated  informed  consent  documents, and upon request  any recruitment 
material and handouts or surveys intended for the participants, prior to recruitment and enrollment of participants.  
Any amendments to the protocol or consent materials will be approved by [CONTACT_168756]. IRB review and approval will occur at least annually throughout the enrollment and follow -up of participants and may cease if annual review is no longer required by [CONTACT_106887]. The investigator will notify the IRB of deviations from the protocol and reportable 
SAEs, as applicable to the IRB policy. 
Each  institution  engaged  in this research  will hold  a current Federal  Wide  Assurance (FWA)  issued 
by [CONTACT_168757]. The IRB/IEC  will determine  that adequate provisions are made  for soliciting  the permission  of each 
participant.  
 
Informed Consent Process  
 
Informed consent is a  process that is initiated  prior to an individual agreeing to participate  in a trial 
and continuing throughout the individual’s trial participation. Before any study procedures are 
performed, informed  consent  will be obtained from the participant and documented. Participants  will 
receive a concise and focused presentation of key information about the clinical trial, verbally and 
with a written  ICF. The explanation will be organized and presented  in lay terminology  and language 
that facilitates understanding why one might or might not want to participate.  
An investigator or designee will describe the protocol to potential participants  face-to-face.  The key 
information about the purpose of the study, the procedures, and experimental aspects of the study, risks and discomforts, any expected benefits to the participant, and alternative treatment will be 
presented first to the participant.  

DMID  Protocol  15-0037  Version  11.0 
72  
 Renal Pharmacokinetics  11 April  2024  
Participants  will also receive an explanation that the trial involves research,  and a detailed  summary 
of the proposed study procedures and study interventions/products. This  will include aspects of the 
trial that are experimental, the probability  for random assignment to treatment  groups, any expected 
benefits, all possible risks (including a statement that the particular treatment or procedure may 
involve risks to the participant or to the unborn child, if the participant is or may become pregnant, 
that are currently  unforeseeable),  the expected  duration of the participant’s  participation  in the trial, 
alternative procedures that may be available and the important potential benefits and risks of these available alternative procedures.  
Participants will be informed that they will be notified in a timely manner if information becomes 
available that may be relevant to their willingness  to continue participation in the trial. Participants 
will receive an explanation as to whether any compensation and any medical  treatments  are available 
if injury occurs, and, if so, what they consist of, or where further information may be obtained. Participants will be informed of the anticipated financial expenses, if any, to the participant for participating in the trial, as well as any anticipated prorated payments, if any, to the participant for 
participating in the trial. They will be informed o f whom to contact (e.g., the investigator) for 
answers to any questions relating to the research project. 
Information will also include the foreseeable circumstances and/or reasons under which the 
participant’s participation in the trial may be terminated. The participants will be informed that participation is voluntary and that they are free to withdraw from  the study for any reason at any 
time without penalty or loss of benefits to which the participant is otherwise entitled.  
The extent of the confidentiality  of the participants’ records will be defined, and participants  will be 
informed that applicable data protection legislation will be followed. Participants will be informed that the monitor(s), auditors(s), IRB, NIAID, and regulatory authority(ies) will be granted direct 
access  to the participant’s  original medical  records for verification  of clinical  trial procedures and/or 
data without violating  the confidentiality of the participant,  to the extent  permitted  by [CONTACT_168758], and that, by [CONTACT_2960] a written ICF, the participant is authorizing such access. 
Participants will be informed that records identifying the participant will be kept confidential, and, 
to the extent  permitted  by [CONTACT_29695]/or regulations, will not be made publicly available 
and, if the results of the trial are published, the participant’s identity will remain confidential. 
Participants will be informed whether private information collected from this research and/or 
specimens will be used for additional research, even if identifiers are removed.  
Participants will be allowed sufficient time to consider participation in this research trial and have 
the opportunity to discuss this trial with their family,  friends, or legally  authorized  representative,  or 
think about it prior to agreeing to participate.  
ICFs will be IRB -approved, and participants will be asked to read and review the consent form. 
Participants  must sign the ICF prior to starting  any study procedures being done specifically  for this 
trial. 
DMID  Protocol  15-0037  Version  11.0 
73  
 Renal Pharmacokinetics  11 April  2024  
Once  signed, a copy of the ICF will be given to the participant(s)  for their records.  The participant(s) 
may withdraw consent at any time throughout the course of the trial. The rights and welfare of the 
participant(s) will be protected  by [CONTACT_168759].  
Study personnel may employ recruitment efforts  prior to obtaining study consent if a patient -specific 
screening consent is on record or if the IRB has agreed that chart review is allowed without a fully 
executed screening consent. In cases where there is not a patient -specific screening consent on 
record, site staff may pre- screen via chart review and refer potential participants to the Research 
staff.  Research  staff  would obtain written  consent per the standard  informed  consent process before 
conducting protocol -specific screening activities.  
New information will be communicated by [CONTACT_7880] [INVESTIGATOR_154374]. The ICF will be updated, and participants will be re -
consented per IRB requirements, if necessary. Participant s will be given a copy of all ICFs that they 
sign. 
 
Special  Populations  
 
This trial will  be inclusive of participants age 18-85 years of age who meet  the participant  inclusion 
criteria  (see Section  5.1.1) and do not meet  any of the participant exclusion criteria  (see Section  
5.1.2),  regardless of religion, sex, or ethnic  background. CKD  is mostly seen in adults, and 
participants enrolled in the control arms must meet certain criteria to match the CKD participants. Therefore, no one under the age of [ADDRESS_196757] by [CONTACT_3486], their staff, and 
the sponsor(s) and their agents. This confidentiality includes documentation, investigation data, 
participant’s clinical information, and all other information generated during participation in the 
study.  
No information concerning the study, or the data generated from the study, will be released to any unauthorized third  party  without prior written  approval of the DMID and the participant.  Participant 
confidentiality will be maintained when study results are published or discussed at conferences.  
The study monitor or other authorized representatives of the sponsor or governmental regulatory 
agencies may inspect all documents and records required to be maintained by [CONTACT_093], 
including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for 
the participants in this study. The clinical study site will permit access to such records. All records will be kept locked, and all computer entry  and networking programs will be carried  out with coded 

DMID  Protocol  15-[ADDRESS_196758] the site will be identified only by a coded number. 
 
Certificate  of Confidentiality  
 
As this research is funded by [CONTACT_7681] (NIH), it is covered by [CONTACT_168760] a Certificate of Confidentiality. By [CONTACT_122842], researchers 
cannot be forced  to disclose or provide, in  any federal,  state,  or local  civil,  criminal,  administrative, 
legislative,  or other proceeding, the name [CONTACT_168778], document, or 
biospecimen that contains identifiable, sensitive information about the individual and that was created or compi[INVESTIGATOR_168704], unless such disclosure or use is made with the 
consent of the individual to whom the information, document, or biospecimen pertains. 
The Certificate cannot be used to resist a demand for information from personnel of the US 
Government that is used for auditing  or evaluation  of federally  funded projects,  like this trial, or for 
information that must be released to meet the requirements of the Federal FDA.  
A Certificate of Confidentiality does not prevent the participant from voluntarily releasing 
information  about themselves  or their involvement in this research. If  any person or agency obtains 
a written  consent  to receive research  information, then the researchers may not use the Certificate  to 
withhold that information.  
The Certificate of Confidentiality does not cover matters that must be legally reported, including 
child and elder abuse, sexual abuse, wanting to harm themselves or others, and certain infectious 
diseases that meet the criteria for reporting. In these cases, researchers may report information that 
would identify a participant without the participant’s consent. 
The release of individual private information or specimens for other research will only occur if 
consent was obtained from the individual to whom the information, document, or biospecimen 
pertains, or for the purposes of other research that the release complie s with the applicable Federal 
regulations governing the protection of human participants in research.  
 
Costs,  Participant Compensation,  and Research  Related  Injuries  
 
There  is no cost to participants for the research  tests,  procedures,  and study product while  taking part 
in this trial. Procedures and treatment for clinical care may  be billed  to the participant,  participant’s 
insurance or third party. Participants may be compensated for their participation in this trial. 
Compensation will be in accordance with the local  IRB’s  policies and procedures,  and participant to 
IRB approval. 
If it is determined by [CONTACT_168761] [INVESTIGATOR_122767] a participant as a direct result of the tests 
or treatments that are done for this trial, then referrals to appropriate health care facilities will be 
provided to the participant. Study personnel will  try to reduce, control, and treat any complications 
from this trial. Immediate  medical  treatment  may be provided by [CONTACT_168762]. No financial 

DMID  Protocol  15-0037  Version  11.0 
75  
 Renal Pharmacokinetics  11 April  2024  
compensation will be provided to the participant by [CONTACT_122845], NIH to the participant, or by [CONTACT_168763].  
DMID  Protocol  15-0037  Version  11.0 
76  
 Renal Pharmacokinetics  11 April  2024  
 
10 STATISTICAL CONSIDERATIONS  
 
Study Hypotheses  
 
FDA guidance document suggests using a reduced PK design for drugs that are predominantly 
metabolized or secreted in the bile [38]. In a reduced PK study design, the trial compares PK in 
patients with normal renal function and to patients with severe renal impairment and patients with 
ESRD  not yet on dialysis. If the reduced  PK study shows at least a 50% increase in AUC in patients 
with severe renal impairment and patients with ESRD not yet on dialysis relative to the matched healthy controls, a “full” renal impairment study in patients with all intermediate levels of renal function impairment should be conducted [ 38]. Otherwise, no further study is recommended. 
In the current study, Part A is considered the reduced PK study in which the geometric mean ratio 
of AUC (AUC
last and area under the plasma concentration -time curve from time zero to infinity 
[AUC ∞]) will be determined comparing Group 2 participants (Severe renal impairment and ESRD, 
not on dialysis) to matched  Group 1A participants  (healthy participants  with normal GFR).  The ratio 
of geometric mean AUCs and 90% confidence interval (CI) of the parent compound will be 
considered in determining whether to continue with a full renal impairment study (enrollment of subsequent cohorts in Part B). Interim PK data of the parent compound will be reviewed by [CONTACT_168764] 
B. For further details, please refer to the PK Manual.  
In Part B, the primary intent will be to estimate PK parameters of the parent compound and 
metabolites and model the relationship between measures of renal function and the PK parameters to determine whether dosage adjustment is required for patients with impaired renal function. 
Estimates and CIs will be utilized rather than formal hypothesis tests.  
No formal hypothesis tests are planned for safety analyses, but safety data will be collected and 
analyzed.  
 
Sample  Size Considerations  
 
A sample size of [ADDRESS_196759]  for renal  impairment PK studies.  Prior studies of pretomanid 
(PA-824) with similar dosing (200 to 250 mg) have  estimated  coefficients  of variation  (CV)  of 16% 
to 33% for the AUC after a single dose in healthy adult participants. Assuming a 20% CV for the 
AUC  of both groups, the probability of observing at least a 50% increase in the geometric  mean  ratio 
of AUCs  given a true 100% increase is >99%. Figure [ADDRESS_196760] a 
50% increase in the geometric  mean  ratio for other  potential scenarios.  The probability of the lower 
bound of the 90% CI for the geometric mean ratio of AUCs being at least 1.5 in this scenario is 
approximately 70%. 

DMID  Protocol  15-0037  Version  11.0 
77  
 Renal Pharmacokinetics  11 April  2024  
Figure  3: Probability  of Observing  at Least  50% Increase by [CONTACT_168765]=coefficients  of variation  
The sample size per arm in Part B was chosen based on feasibility and appropriateness for a PK 
study in renal impaired participants to estimate group differences in PK parameters with adequate 
precision. Assuming an observed 2 -fold difference between each rena l impairment group and 
matched controls with no correlation between matched pairs and a coefficient of variation of 20%, a 90% CI for the fold difference between groups is (1.70, 2.35). 
 
Treatment  Assignment  Procedures  
 
Randomization Procedures  
 
There  will be no randomization  performed  for this study. Participants  will be assigned  to study 
groups based on eGFR. 
1.[ADDRESS_196761]  a 50% Increase  
DMID  Protocol  15-0037  Version  11.0 
78  
 Renal Pharmacokinetics  11 April  2024  
10.3.2 Masking Procedures  
 
Not applicable. This is an open- label study.  
 
Planned Interim  Analyses  
 
Interim Safety  and PK Review  
 
A study team  and SMC  safety  and PK review  will occur after Part A 6 participants  in Group 2 (severe 
renal  impairment  and ESRD,  not on dialysis) and Group 1A their matched  controls are enrolled  and 
completed  follow-up through Day 12 (Visit 02). This review  will decide if Part B will be conducted 
and whether enrollment for Group 3 (eGFR 60- 89), and Group 4 (eGFR 30- 59) will occur. The 
interim safety and PK review will present data by [CONTACT_19313], including AEs, SAEs, clinical laboratory 
tests, vital signs, and 12- lead ECG, and PK analysis of pr etomanid. Cumulative data for all 
participants enrolled will be included in the safety and PK reviews.  
 
Final  Analysis  Plan 
 
Analysis Populations  
 
The following sections define the analysis populations for the analysis and reporting of data.  
 
[IP_ADDRESS] Safety  Analysis Population  
 
The safety  analysis population will include all participants  who received  study product.  
 
[IP_ADDRESS] PK Analysis Population  
 
The PK analysis population will consist of participants who received pretomanid and provided 
sufficient  bioanalytical assessment  results  to calculate reliable  estimates of the PK parameters.  Any 
participants  or data values excluded from PK analyses will be identified,  along with their reason  for 
exclusion, in the clinical study report. 
 
Analysis of Primary  Endpoint  (PK for Pretomanid)  
 
All PK parameters will be estimated through a non- compartmental analysis using a validated 
installation of Phoenix WinNonlin (Certara, Princeton, NJ) version 8.0 or later. The recorded true 
time points will be  used for PK calculation.  Estimated total  plasma PK parameters  are listed below. 
Plasma PK of  P retomanid  
The plasma PK of a single dose of pretomanid  will be assessed  from serial  blood samples collected 
up to 1 hour pre-dose (Day  1) and at multiple  time points post dosing: 1, 2, 4, 5, 6, 8, 12, 16, 24, 36, 

DMID  Protocol  15-0037  Version  11.0 
79  
 Renal Pharmacokinetics  11 April  2024  
48, 72, and 96 hours. The primary  outcome measure will be total plasma concentration  of 
pretomanid.  The following PK parameters  will be determined  using total pretomanid  concentrations:  
Cmax: Maximum plasma  concentration  
Tmax : Time  to peak  (maximum) plasma  concentration  
AUC last: Area  under the plasma  concentration -time curve from  time zero to time of last 
measurable concentration  
AUC ∞: Area  under the plasma concentration- time curve from time zero to infinity  
%AUC ex: Percentage of AUC ∞ obtained by [CONTACT_5259] 
t1/2 : Terminal-phase elimination half- life 
λz: Apparent first- order  terminal  elimination  rate constant 
CL/F: Apparent clearance  
Vd/F: Apparent volume of distribution  
Urine  PK of  Pretomanid  
The urine PK of a single dose of pretomanid will be assessed from urine collected up to [ADDRESS_196762] -dose. Volume of urine will be 
measured and recorded at each of these time intervals. Urine samples will be stored at room 
temperature  and then frozen  at -20°C within  24 hours. Urine  will be stored  in ≤100  mL aliquots 
at -20°C until shipped to Fisher Bioservices for storage. 
Ae(0-t): Cumulative amount excreted  into the urine  from time  0 to the time  t 
Ae%Dose: Fraction of dose excreted into the urine 
CL R: Renal  clearance  
Details of the statistical analysis will be included in the statistical  analysis plan.  
 
Analysis of Secondary  Endpoint  (Safety)  
 
All safety  analyses  will be presented  using the safety  analysis set. No formal  hypothesis testing  will 
be conducted. 
[IP_ADDRESS] A dverse Events  
 
AEs will be coded using Medical Dictionary for Regulatory Activities® (MedDRA). All AEs that 
occur after the receipt of study product will be summarized using the number of events as well as 
the number and percent of participants experiencing the event. Summaries will be presented by [CONTACT_168766]- renally  impaired  groups and MedDRA level  hierarchy  (system  organ class 
[SOC] and preferred term) as follows:  
• Overall  (i.e., regardless of severity  or relationship  to treatment) 

DMID  Protocol  15-0037  Version  11.0 
80  
 Renal Pharmacokinetics  11 April  2024  
 
• By [CONTACT_168767] (mild, moderate,  severe,  or life-threatening)  
• By [CONTACT_168768],  at each level  of participant summarization  in reporting  incidence of AEs, 
a participant will be counted only once even if the  participant reported one or more events. If more 
than one occurrence of an event is reported, the event of the worst severity or the worst -case 
relationship assessment will be summarized.  
The number of SAEs  is expected  to be small,  as such these events will be reported in detailed  listings 
showing the event description, MedDRA preferred  term and SOC,  event date,  severity,  relatedness, 
and outcome for each event. 
[IP_ADDRESS] Laboratory Parameters  
 
Descriptive summary statistics for laboratory data at admission, Day 12, and change from baseline 
will be presented by [CONTACT_168769]- renally impaired control groups. For change from 
baseline summaries,  participants  with an undefined change from  admission, because of missing  data, 
will be excluded. Graphs,  showing individual participant changes from admission  to Day 12 will be 
presented for each laboratory parameter, by [CONTACT_168769]- renally impaired groups. 
Participants with clinically significant outliers will be identified in listings.  
[IP_ADDRESS] Vital Signs  
 
Descriptive summary statistics of vital signs at Day [ADDRESS_196763] -dose time point (both 
absolute and change) will be summarized by [CONTACT_168770] -renally impaired 
control group. For change from pre -dose summaries, participants with an undefined change from 
pre-dose, because of missing data, will be excluded. 
[IP_ADDRESS] ECG  Data  
 
ECG intervals (QTcF), including change from baseline, will be summarized at the Screening Visit 
00A and Visit 01N using descriptive statistics.  
[IP_ADDRESS] Demographics and Screening  Summaries  
 
Demographic variables (age, gender, race, and ethnicity) and screening characteristics (height, 
weight) will be summarized  by [CONTACT_168766]- renally  impaired  groups. The comparability 
of the groups  for relevant  demographic and screening  characteristics will be assessed  by [CONTACT_168771]/or graphs. No statistical hypothesis tests will be performed. For continuous data, summaries  will include the number of observations, mean,  standard  deviation, median,  [ADDRESS_196764] -dose visits, in addition to screening. 
DMID  Protocol  15-0037  Version  11.0 
81  
 Renal Pharmacokinetics  11 April  2024  
Analysis of Secondary  Endpoint  (PK for M19 and M50)  
 
AUC last, and any other  parameters considered to be of interest,  of the pretomanid  representative 
metabolites M19 and M50 in plasma will be estimated.  
Excretion in urine  of metabolites  M19  and M50 will be estimated.  

DMID  Protocol  15-0037  Version  11.0 
82  
 Renal Pharmacokinetics  11 April  2024  
 
11 ELECTRONIC CASE REPORT FORMS AND ACCESS TO 
SOURCE DATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records in compliance with 
ICH E6, Section 4.9, and regulatory and institutional requirements for the protection of 
confidentiality of participants. Each site will permit authorized rep resentatives of the DMID, its 
designees,  and appropriate regulatory  agencies to examine (and when  required  by [CONTACT_1289], to 
copy) clinical trial records for the purposes of quality assurance reviews, audits, evaluation of the study safety and progress . These representatives will be permitted access to all source data and 
source documents.  
Source data are all information  in original records  (and certified  copi[INVESTIGATOR_63062])  of clinical 
findings, observations, or other activities in a clinical trial necessary for the reconstruction and 
evaluation of the trial. Source data should be attributable, legible, contemporaneous, original, 
accurate, and complete. Each participating site w ill maintain appropriate medical and research 
records for this trial, in compliance with ICH GCP,  regulatory, and institutional requirements.  Study 
data will be collected on paper DCFs and entered into the eCRF, or data will be entered into the eCRF  from electronic  source documents. Data  recorded  in the eCRF  derived from source documents 
should be consistent with the data recorded on the source documents. 
DMID  Protocol  15-0037  Version  11.0 
83  
 Renal Pharmacokinetics  11 April  2024  
 
12 QUALITY  CONTROL  AND  QUALITY ASSURANCE  
 
Following a written DMID -accepted site quality management plan, each participating site is 
responsible for conducting routine quality assurance and quality control (QC)  activities  to internally 
monitor study  progress and protocol compliance. The  site PI [INVESTIGATOR_71464] - 
related sites, source data/DCFs, and reports for the purpose of monitoring and auditing by [CONTACT_103], and inspection by [CONTACT_168772]. The  site PI [INVESTIGATOR_168705]. 
The SDCC will implement QC procedures beginning with the data entry system and generate data 
QC checks that will be run on the database. Any missing data or data anomalies will be 
communicated to the participating sites for clarification and resolution.  
DMID  Protocol  15-[ADDRESS_196765] KEEPI[INVESTIGATOR_168706] a complete medical history and ensure the accuracy, 
completeness,  legibility,  and timeliness  of the data reported. Section  11 details  source data collection 
formats.  Site staff will be trained  on the use of the data system  and error  correction  procedures.  The 
site will include on the Delegation  of Authority  log personnel trained  and authorized to enter  original 
source data.  
The sponsor and/or its designee will provide guidance to the site PI [INVESTIGATOR_168707].  
 
Data Coordinating Center/Biostatistician Responsibilities  
 
Data collection is the responsibility of the study personnel at each participating clinical site under the supervision of the site PI. During this trial, the site PI [INVESTIGATOR_168708]. 
The Data  Coordinating Center  (DCC)  for this study  will be responsible for data management,  quality 
review, analysis, and reporting of the study data. 
 
Data Capture  Methods 
 
Clinical data (including, but not limited to, AEs/SAEs, concomitant medications, medical history, 
physical assessments, and clinical laboratory values) will be collected on  DCFs by [CONTACT_168773] a [ADDRESS_196766] protection and internal quality checks, such as automatic  range checks,  to identify  data that appear inconsistent, incomplete,  or inaccurate.  
 
Types  of Data 
 
Data  for this trial will include safety  and outcome measures (e.g., clinical  and PK data).  
 
Study Records  Retention 
 
Study records and reports including, but not limited to, DCFs, source documents, ICFs, laboratory 
test results, and study product disposition records will be retained for a minimum of [ADDRESS_196767] for which it is being investigated; or, if no 
application  is to be filed or if the application is not approved for the study product, until 2 years  after 
the investigation is discontinued and FDA has been  notified. These documents will be retained  for a 

DMID  Protocol  15-0037  Version  11.0 
85  
 Renal Pharmacokinetics  11 April  2024  
longer period, however, if required by [CONTACT_427]. ICFs for future use will be maintained as 
long as the sample/specimen exists.  
No records will be destroyed without written consent of the sponsor. It is the responsibility of the 
sponsor to inform the investigator when these documents no longer need to be retained. The 
participating  sites must  contact [CONTACT_168774].  
DMID  Protocol  15-0037  Version  11.0 
86  
 Renal Pharmacokinetics  11 April  2024  
 
14 CLINICAL  MONITORING 
 
Site monitoring is conducted to ensure that the human  participants’ protections, study and laboratory 
procedures, study intervention  administration, and data collection  processes are of high quality and 
meet sponsor, ICH/GCP guidelines and applicable regulations, and that this trial is conducted in 
accordance with the protocol, protocol -specific MOP, and applicable sponsor standard operating 
procedures. DMID, the sponsoring agency, or its designee wil l conduct site monitoring visits as 
detailed in the clinical monitoring plan.  
Site visits  will be made  at standard  intervals  as defined by [CONTACT_168775]. Monitoring visits will include, but are not limited to, review of regulatory 
files, accountability records, eCRFs, ICFs, medical and laboratory reports, and protocol and GCP compliance.  Site monitors  will have access to  each  participating  site,  study  personnel, and all  study 
documentation according to the DMID -approved site monitoring plan. Study monitors will meet 
with site PIs to discuss any problems and actions to be taken and document visit findings and discussions.  
DMID  Protocol  15-0037  Version  11.0 
87  
 Renal Pharmacokinetics  11 April  2024  
 
15 PUBLICATION  POLICY  
 
This trial will be conducted in accordance with the NIH Public Access Policy, which ensures that 
the public has access to the published results of NIH funded research.  It requires  scientists to submit 
final peer- reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed 
Central (https://www.ncbi.nlm.nih.gov/pmc/)  upon acceptance for publication. 
Refer to: 
• NIH Public Access Policy, http://publicaccess.nih.gov/  
• NIH Office  of Extramural  Research  (OER)  Grants  and Funding, 
http://grants.nih.gov/grants/oer.htm  
As of January 2018, all clinical  trials  supported by [CONTACT_168776].gov, 
no later than [ADDRESS_196768] applied for certification of delayed posting. 
As part of the result  posting a copy of this protocol  (and its amendments) and a copy of the Statistical 
Analysis Plan will be posted on ClincialTrials.gov.  
For this trial the responsible party  is DMID which  will register  the trial and  post results. 
The responsible party plans not to request certification of delayed posting. 
Refer to: 
• Public Law 110-85, Section 801, Clinical  Trial Databases  
• 42CFR11  
• NIH NOT -OD-16-[ADDRESS_196769] 
tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epi[INVESTIGATOR_5541], 1993. 
22(6): p. 1154-8. 
3. Colditz,  G.A.,  et al., Efficacy  of BCG  vaccine in the prevention  of tuberculosis.  Meta -analysis 
of the published literature. JAMA, 1994. 271(9): p. 698-702. 
4. ATS,  C., IDSA,  Treatment  of tuberculosis. MMWR  Recommendations and Reports  2003.  
52 (RR-11) : p. 1- 77. 
5. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep, 2000. 49(RR- 6): p. 1-51. 
6. Center  for Disease,  C.P., Recommendations for use of an isoniazid- rifapentine  regimen  with 
direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep, 2011. 60(48): p. 1650-3. 
7. Organization,  W.H., Global Tuberculosis Report 2014. 2014. 
8. Pi[INVESTIGATOR_168709], E., et al., Long- term outcomes of patients with extensively drug -resistant 
tuberculosis in South Africa: a cohort study. Lancet, 2014. 383 (9924): p. 1230-9. 
9. Jha, V., et al., Chronic kidney disease:  global dimension and perspectives.  Lancet,  2013.  
382(9888): p. 260- 72. 
10. Kurts, C., et al., The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol, 2013. 13(10): p. 738-53. 
11. Romanowski, K., et al., Tuberculosis and chronic kidney disease: an emerging global 
syndemic. Kidney Int, 2016. 90(1): p. 34-40. 
12. Zuo, L., M. Wang, and A. Chinese Association of Blood Purification Management of 
Chinese Hospi[INVESTIGATOR_307],  Current  burden and probable increasing  incidence of ESRD  in China. Clin 
Nephrol, 2010. [ADDRESS_196770] 1 : p. S20- 2. 
13. Carrero, J.J. and P. Stenvinkel, Inflammation in end- stage renal disease--what have we 
learned in 10 years? Semin Dial, 2010. 23(5): p. 498-509. 
14. Nahid, P., et al., Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society  of America  Clinical Practice Guidelines: Treatment 
of Drug-Susceptible Tuberculosis. Clin Infect Dis, 2016. 63(7): p. e147-e195. 
15. Alsultan, A. and C.A. Peloquin, Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs, 2014. 74(8): p. 839-54. 
16. Launay- Vacher, V., H. Izzedine, and G. Deray, Pharmacokinetic considerations in the 
treatment  of tuberculosis in patients with renal failure. Clin Pharmacokinet,  2005. 44(3): p. 
221-35. 
17. B
aghaei,  P., et al., Impact of chronic renal failure on anti-tuberculosis treatment outcomes.  
Int J Tuberc Lung Dis, 2014. 18(3): p. 352- 6. 
18. Global Alliance  for TB Drug  Development, Investigator's Brochure:  PA-824 (Pretomanid), 
v22. 31 January 2023. 
19. Pa-824. Tuberculosis (Edinb), 2008. 88(2): p. 134-6. 
20. Stover, C.K.,  et al., A small -molecule nitroimidazopyran drug candidate for the treatment  of 
tuberculosis. Nature, 2000. 405(6789): p. 962-6. 
21. Manjunatha, U., H.I. Boshoff, and C.E. Barry, The mechanism of action of PA -824: Novel 
insights from transcriptional profiling. Commun Integr Biol, 2009. 2(3): p. 215-8. 
DMID  Protocol  15-0037  Version  11.0 
89  
 Renal Pharmacokinetics  11 April  2024  
22. Singh, R., et al., PA- 824 kills nonreplicating Mycobacterium tuberculosis by [CONTACT_168777]. Science, 2008. 322(5906): p. 1392-5. 
23. Diacon, A.H., et al., Early bactericidal activity and pharmacokinetics of PA -824 in smear - 
positive tuberculosis patients. Antimicrob Agents Chemother, 2010. 54(8): p. 3402-7. 
24. Tasneen, R., et al., Sterilizing activity of novel TMC207 - and PA -824- containing regimens 
in a murine model of tuberculosis.  Antimicrob  Agents Chemother, 2011. 55(12): p. 5485-92. 
25. Tyagi, S.,  et al., Bactericidal activity  of the nitroimidazopyran PA-824 in  a murine model of 
tuberculosis. Antimicrob Agents Chemother, 2005. 49(6): p. 2289-93. 
26. Lenaerts,  A.J., et al., Preclinical testing  of the nitroimidazopyran PA-[ADDRESS_196771] 
Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents 
Chemother, 2005. 49(6): p. 2294-301. 
27. Ahmad, Z., et al., PA-824 exhibits  time-dependent activity  in a murine model of tuberculosis.  
Antimicrob  Agents Chemother, 2011. 55(1): p. 239- 45. 
28. Tasneen, R., et al., Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrob Agents Chemother, 2016. 60(1): p. 270-7. 
29. Diacon, A.H.,  et al.,  Phase II dose-ranging trial of the early bactericidal  activity  of PA-824. 
Antimicrob  Agents Chemother, 2012. 56(6): p. 3027- 31. 
30. Diacon, A.H., et al., 14-day bactericidal activity  of PA-824, bedaquiline, pyrazinamide, and 
moxifloxacin combinations: a randomised trial. Lancet, 2012. 380(9846): p. 986-93. 
31. Dawson,  R., et al., Efficiency  and safety  of the combination of moxifloxacin, pretomanid (PA- 
824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open- label, partly randomised trial in patients with drug -susceptible or drug- resistant 
pulmonary tuberculosis. Lancet, 2015. 385(9979): p. 1738-1747. 
32. Diacon, A.H., et al., Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med, 2015. 191(8):  
p. 943- 53. 
33. C
onradie, F., et al., Treatment of Highly Drug- Resistant Pulmonary Tuberculosis. N Engl J 
Med, 2020. 382(10): p. 893-902. 
34. TB Alliance,  PA-824 has a New Generic Name:  [CONTACT_168779]. 2014.  
35. Dooley, K.E., et al., Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA -824 with concomitant lopi[INVESTIGATOR_054] -ritonavir, efavirenz, or rifampin. 
Antimicrob Agents Chemother, 2014. 58(9): p. 5245-52. 
36. Dogra, M., et al., Comparative bioactivation of the novel anti-tuberculosis agent  PA-824 in 
Mycobacteria and a subcellular fraction of human liver. Br J Pharmacol, 2011. 162(1): p. 226-36. 
37. Strunk, A.K., et al., Single- and multiple -dose pharmacokinetics of ethambutol and 
rifampi[INVESTIGATOR_168710] a tuberculosis patient with acute respi[INVESTIGATOR_168711]. Int J Infect Dis, 2016. 42: p. 1-3. 
38. Center for Drug Evaluation and Research, Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function – Study Design, Data Analysis, and Impact on 
Dosing, U.S. Department of Health and Human Services, Editor. 2020, Food and Drug Administration  
39. Matzke, G.R., et al., Drug dosing consideration in patients with acute and chronic kidney disease -a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). 
Kidney Int, 2011. 80(11): p. 1122- 37. 
DMID  Protocol  15-0037  Version  11.0 
90  
 Renal Pharmacokinetics  11 April  2024  
40. Center for Drug Evaluation and Research, Assessing the Effects of Food on Drugs in INDs 
and NDAs — Clinical Pharmacology Considerations Guidance for Industry , U.S. 
Department of Health and Human Services, Editor. 2019, Food and Drug Administration,. 
41. Center  for Drug  Evaluation and Research,  Clinical Drug  Interaction  Studies  — Cytochrome 
P450 Enzyme - and Transporter -Mediated Drug Interactions Guidance for Industry , US 
Department of Health and Human Services, Editor. 2020, Food and Drug Administration,. 
42. FDA.  Drug  Development  and Drug  Interactions: Table of Substrates, Inhibitors  and 
Inducers . 06/05/2023 [cited  2023; Available  from: https:/ /www.fda.gov/drugs/drug-  
interactions -labeling/drug -development -and-drug-interactions -table -substrates- inhibitors - 
and-inducers. 
DMID  Protocol  15-0037  Version  11.0 
91  
 Renal Pharmacokinetics  11 April  2024  
 
17 APPENDICES  
 
APPENDIX  A: Schedule of Study Procedures and Evaluations  
APPENDIX B: Venipuncture Volumes (mL)  
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
92  
  
APPENDIX A: Schedule of Study Procedures  and Evaluations  
 
Study  Visit  00A 00B 00C 01A 01B 01C 01D 01E 01F 01G 01H 01I 01J 01K 01L 01M 01N 021 03 Early  
Term  
Study  Day Screen  
-28 to -7 Admit  
-1 1 1 1 1 1 1 1 1 1 2 2 3 4 5 12 
± 2d 85 
+7d  
 
 
 
PK Time Window     
Up to 1 hour 
Pre-dose8 
1 hr ( ± 10 min) 
2 hr ( ± 10 min) 
4 hr ( ± 10 min) 
5 hr ( ± 10 min) 
6 hr ( ± 10 min) 
8 hr ( ± 10 min) 
12 hr ( ± 10 min) 
16 hr ( ± 10 min) 
24 hrs ( ± 1hr) 
36 hrs ( ± 1hr) 
48 hrs ( ± 1hr) 
72 hrs ( ± 4hrs)  
 
 
96 hr ( ± 4hrs)     
Obtain Written Informed  
Consent  X                    
Verify  Eligibility  X  X X                 
Reconfirm participant’s  
willingness  to participate   X X                  
Medical  History  X  X X            X X X  X 
Concomitant  Medications  X  X2 X2 X2 X2 X2 X2 X2 X2 X2 X2 X2 X2 X2 X X X  X 
12-Lead ECG  X                X    
Vital  Signs (Oral  Temp,  
Sitting Pulse  and BP)3 X   X       X  X  X X X X  X 
Physical Examination  X                    
Targeted  PE if needed     X X X X X X X X X X X X X X X  X 
Height  and Weight  X                    
Urine  Pregnancy  Test4  X X X              X  X 
Placement  of Peripheral 
Catheter (if applicable)     
X5  
X5                 
HIV,  HBsAg,  HCV  X                    
Safety  and Basic Lab 
Testing6 X                X X  X 
DMID  Protocol  15-0037 
Renal Pharmacokinetics  Version  11.0 
11 April  2024  
93  
  
Study  Visit  00A 00B 00C 01A 01B 01C 01D 01E 01F 01G 01H 01I 01J 01K 01L 01M 01N 021 03 Early  
Term  
Study  Day Screen  
-28 to -7 Admit  
-1 1 1 1 1 1 1 1 1 1 2 2 3 4 5 12 
± 2d 85 
+7d  
 
 
PK Time Window     
Up to 1 hour 
Pre-dose8 
1 hr ( ± 10 min) 
2 hr ( ± 10 min) 
4 hr ( ± 10 min) 
5 hr ( ± 10 min) 
6 hr ( ± 10 min) 
8 hr ( ± 10 min) 
12 hr ( ± 10 
min) 
16 hr ( ± 10 
min) 
24 hrs ( ± 1hr) 
36 hrs ( ± 1hr) 
48 hrs ( ± 1hr) 
72 hrs ( ± 4hrs)  
 
 
96 hr ( ± 4hrs)     
Urine  Drug  Screen  and 
Alcohol screening   X X                  
In-house Confinement    X X X X X X X X X X X X X      
Study  Product  
Administration7    X                 
Blood  for PK    X8 X X X X X X X X X X X X X    
Urine  collection  for PK 
and volume  
measurement9     
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X    
Discharge  from  
Hospi[INVESTIGATOR_307]12               X      
Remove Intravenous  
Catheter  (if applicable)                X      
Targeted  Review  of 
Systems for Renal  
Participants                      
X 
AE/SAE Assessment     X X X X X X X X X X X X X X X X10 X 
Pregnancy  Assessment                    X  
Phone Call                   X  
AE=adverse event; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; ECG=electrocardiogram; eGFR=estimated 
glomerular filtration rate; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human immunodeficiency virus; PE=physical examination; 
PK=pharmacokinetic; SAE=serious adverse event  
[ADDRESS_196772], ALT, total bilirubin,  BUN, serum  creatinine  (includes  eGFR), serum  potassium  and magnesium  will be checked.  
[ADDRESS_196773] doses. Study participants should eat this meal in 30 ± 10 minutes or less; how ever, 
pretomanid should be administered 30 ± [ADDRESS_196774]-dosing.  PK urine  sample  collection 
during the 48 -72 hours and 72 -96 hours may be performed at home (i.e., Day 4 and Day 5).  
10 SAEs only from  study drug administration  to Day 85 + 7 days.  
11 Alcohol  testing  can be done  on blood or breath  if breathalyzer  is used for alcohol  testing.  
12 Participants  may remain  in the hospi[INVESTIGATOR_168712].  
DMID  Protocol  15-0037  Version  11.0 
95  
 Renal Pharmacokinetics  11 April 2024  
APPENDIX B: Venipuncture  Volumes  (mL) 
 
Study  Visit  00A 00B 00C 01A 01B 01C 01D 01E 01F 01G 01H 01I 01J 01K 01L 01M 01N 02 03 
Study  Day Screen  
-28 to -7 Admit  - 
1 1 1 1 1 1 1 1 1 1 2 2 3 4 5 12 ± 
2d 85+7  
d 
 
 
 
PK Time Window     
Up to 1 hour Pre- 
dose 
1 hr ( ± 10  min) 
2 hr ( ± 10  min) 
4 hr ( ± 10  min) 
5 hr ( ± 10  min) 
6 hr ( ± 10  min) 
8 hr ( ± 10  min) 
12 hr ( ± 10 min) 
16 hr ( ± 10 min) 
24 hrs ( ± 1 hr) 
36 hrs ( ± 1 hr) 
48 hrs ( ± 1 hrs) 
72 hrs ( ± 4 hrs) 
96 hrs ( ± 4 hrs)   
HIV,  HBsAg,  HCV  12                   
Blood  for Safety  10                10 10  
Blood  to Screen for 
Alcohol1  6 6                 
Blood  for PK    4 4 4 4 4 4 4 4 4 4 4 4 4 4   
Total  22 6 6 4 4 4 4 4 4 4 4 4 4 4 4 4 4 10 0 
Cumulative  Total 
(Cumulative total  
plus next  total)   
22  
28  
34  
38  
42  
46  
50  
54  
58  
62  
66  
70  
74  
78  
82  
86  
90  
100  
100 
HBsAg=hepatitis  B surface antigen; HCV=hepatitis  C virus;  HIV=human immunodeficiency  virus;  PK=pharmacokinetic  
 
1 Alcohol  testing  can be done  on blood or breath  if breathalyzer  is used for alcohol  testing.  